Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
- Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.24 per share, missing the Zacks Consensus Estimate of $1.47 per share. This compares to earnings of $0.82 per share a year ago.
- 10/30/2024
|
Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
- INGREZZA® (valbenazine) Third Quarter Net Product Sales of $613 Million Representing 26% Year-Over-Year Growth INGREZZA ® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.30 - $2.32 Billion Board Authorizes $300 Million Share Repurchase Plan SAN DIEGO , Oct. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2024 and provided an update on its 2024 financial guidance. "With continued INGREZZA growth across the tardive dyskinesia and Huntington's disease chorea indications, FDA Priority Review for crinecerfont in congenital adrenal hyperplasia, a deep neuroscience focused pipeline and a strong balance sheet, we are confident in our ability to help more patients than ever before," said Kyle W.
- 10/30/2024
|
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
- Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/23/2024
|
Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)
- Neurocrine Biosciences' Ingrezza has grown into a multibillion-dollar drug, but the company's stock has underperformed the S&P 500 since 2019. Neurocrine's NBI-1117568 demonstrated encouraging Phase 2 schizophrenia data, though dose inconsistencies raised questions about efficacy. The stock's recent decline is an overreaction, presenting a buying opportunity given its CNS pipeline and Ingrezza's ongoing growth.
- 10/10/2024
|
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results
- Conference Call and Webcast Scheduled for Wednesday, October 30 SAN DIEGO , Oct. 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m.
- 10/09/2024
|
Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
- KINECT®-HD2 Is the First Prospective Clinical Trial to Include Patients Taking Antipsychotic Medication in a Study Evaluating a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor for the Treatment of Huntington's Disease Chorea Findings Presented at the 2024 MDS International Congress of Parkinson's Disease and Movement Disorders® SAN DIEGO , Sept. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT®-HD2 study of INGREZZA® (valbenazine) capsules for the long-term treatment of adults with chorea associated with Huntington's disease.
- 09/30/2024
|
Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
- SAN DIEGO , Sept. 19, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit at 11:00 a.m.
- 09/19/2024
|
Neurocrine's experimental drug misses primary goal in schizophrenia trial
- Neurocrine Biosciences said its experimental drug did not achieve the primary goal in a mid-stage trial aimed at improving cognitive function in patients with schizophrenia.
- 09/12/2024
|
Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
- Second Phase 2 Study for Luvadaxistat Fails to Meet Primary Endpoint as Potential Treatment for Cognitive Impairment Associated with Schizophrenia Results Confounded by Variability in Cognition Measures Across Population Studied and Potential Imbalance in Baseline Characteristics of Enrolled Subjects Neurocrine Biosciences to Focus Resources on Phase 3 Clinical Development of NBI-1117568 for Schizophrenia and NBI-1065845 for Major Depressive Disorder SAN DIEGO , Sept. 12, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its ERUDITE™ Phase 2 clinical study of investigational compound luvadaxistat (NBI-1065844) failed to meet its primary endpoint as a potential treatment to improve cognitive impairment in patients with schizophrenia.
- 09/12/2024
|
Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
- SAN DIEGO , Sept. 10, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the 2024 Cantor Global Healthcare Conference in New York at 3:05 p.m.
- 09/10/2024
|
Why Neurocrine Biosciences Stock Was Tumbling This Week
- The biotech released the results of phase 2 clinical trial of its investigational schizophrenia drug. One of the four doses clearly performed well.
- 08/30/2024
|
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
- Wednesday, Neurocrine Biosciences, Inc. (NASDAQ: NBIX) topline data for its Phase 2 clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia.
- 08/29/2024
|
Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results
- Though data from a mid-stage study shows that treatment with NBIX's schizophrenia drug is effective, results lag behind drugs being developed by its peers.
- 08/29/2024
|
Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data
- Despite Neurocrine Biosciences, Inc. muscarinic receptor drug NBI-'568 not surpassing competitors in Schizophrenia, several other drugs of the same type are being developed for large market indications like Alzheimer's Disease. There are several other shots on goal in targeting the Schizophrenia patient populations using luvadaxistat and others. The global Schizophrenia Drugs Market is forecasted to reach $9.46 billion by 2030.
- 08/28/2024
|
Neurocrine Biosciences to Participate at Investor Conferences in September
- Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 in New York 2024 Wells Fargo Healthcare Conference on September 5 in Boston SAN DIEGO , Aug. 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at two upcoming investor conferences in September. Chief Executive Officer Kevin Gorman, Chief Business Development and Strategy Officer Kyle Gano, and Chief Financial Officer Matt Abernethy will present at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York at 3:20 p.m.
- 08/28/2024
|
Neurocrine Biosciences: Disappointing Data From A Key Readout Hits The Stock Hard
- Neurocrine Biosciences posted disappointing Phase II data for its schizophrenia drug NBI-1117568, driving a steep fall in the share price. NBI-568 came up short in terms of PANSS reduction, with a 7.5pt placebo-adjusted reduction missing the double-digit target the Street wanted to see. Management remains optimistic about '568, planning Phase III trials, but it seems optimistic to think that Phase III results are likely to be good enough to make '568 truly competitive.
- 08/28/2024
|
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
- Wednesday, Neurocrine Biosciences, Inc. NBIX topline data for its Phase 2 clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia.
- 08/28/2024
|
Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
- Tokyo, Japan and Cambridge, UK, 28 August 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – notes the announcement by its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX) that NBI-1117568 (NBI-‘568) has delivered positive topline results from its Phase 2 clinical study in adults with schizophrenia. NBI-'568 is the first investigational, oral, muscarinic M4 selective agonist in development for the treatment of schizophrenia.
- 08/28/2024
|
Neurocrine's schizophrenia drug meets main goal in mid-stage study
- Neurocrine Biosciences said on Wednesday its experimental drug to treat adults with schizophrenia met the main goal in a mid-stage study.
- 08/28/2024
|
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia
- The Once-Daily 20 mg Dose Met the Primary Endpoint, Demonstrating a Statistically Significant 7.5-Point Improvement (p=0.011, 0.61 Effect Size) in the PANSS Total Score Compared to Placebo at Week 6 with an 18.2-Point PANSS Total Score Improvement from Baseline The Once-Daily 20 mg Dose Met Additional Endpoints, Demonstrating Statistically Significant Improvements in Clinical Global Impression of Severity Scale and Marder Factor Score Positive Symptom Change and Negative Symptom Change NBI-'568 Was Generally Safe and Well Tolerated at All Doses Studied The Once-Daily 20 mg Dose Efficacy, Safety and Tolerability Phase 2 Results Support Advancement to Phase 3 in Schizophrenia in Early 2025 Company to Host Conference Call with Management at 8 a.m. EDT SAN DIEGO , Aug. 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive top-line data for its Phase 2 clinical study of NBI-1117568 (NBI-'568) in adults with schizophrenia.
- 08/28/2024
|
Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
- SAN DIEGO , Aug. 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Canaccord Genuity 44th Annual Growth Conference in Boston at 3:30 p.m. Eastern Time on Wednesday, August 14, 2024.
- 08/07/2024
|
Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes"
- Neurocrine (NBIX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 08/06/2024
|
Neurocrine Biosciences Delivering Strong Core Results, And Significant Pipeline Value Could Be On The Way
- Ingrezza sales are on the rise, with a 32% increase in sales in Q2'24, and there is still an attractive runway of growth ahead for the drug. The Phase II results of '845 in major depressive disorder exceeded expectations, potentially adding over $1B to the revenue pool and positioning it as a potential future rival to Spravato. The upcoming Phase II readout for '568 (an M4 agonist) in schizophrenia is a potentially significant value-creation opportunity, but it will likely require a double-digit improvement in PANSS.
- 08/02/2024
|
Compared to Estimates, Neurocrine (NBIX) Q2 Earnings: A Look at Key Metrics
- While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 08/01/2024
|
Neurocrine Biosciences (NBIX) Lags Q2 Earnings Estimates
- Neurocrine Biosciences (NBIX) came out with quarterly earnings of $0.63 per share, missing the Zacks Consensus Estimate of $1.15 per share. This compares to earnings of $0.95 per share a year ago.
- 08/01/2024
|
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
- INGREZZA® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.25 - $2.3 Billion Top-Line Phase 2 Data Readouts for NBI-'568 and Luvadaxistat Remain On Track in Q3 SAN DIEGO , Aug. 1, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2024 and provided an update on its 2024 financial guidance. "At Neurocrine, we are energized by the tremendous opportunity we see to help many more patients, and we are encouraged by our recent progress, including INGREZZA's continued success in treating tardive dyskinesia and Huntington's disease chorea and the FDA's decision to grant Priority Review for crinecerfont to treat congenital adrenal hyperplasia," said Kevin Gorman, Ph.D.
- 08/01/2024
|
Insights Into Neurocrine (NBIX) Q2: Wall Street Projections for Key Metrics
- Evaluate the expected performance of Neurocrine (NBIX) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
- 07/31/2024
|
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/25/2024
|
Neurocrine's Growing Sales, Profits Attracting Big Money
- Sales and profits have been rocketing upwards for Neurocrine Biosciences, Inc. (NBIX), and a recent regulatory approval should continue that trend.
- 07/19/2024
|
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
- SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of a new sprinkle formulation of INGREZZA® (valbenazine) capsules, the #1 prescribed vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease.1 INGREZZA® SPRINKLE (valbenazine) capsules is now available through the same network of specialty and local affiliated pharmacies that distribute INGREZZA. "Only INGREZZA offers a sprinkle formulation to ease administration for individuals living with tardive dyskinesia or Huntington's disease chorea, who often have difficulty swallowing pills," said Eiry W.
- 07/18/2024
|
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
- Conference Call and Webcast Scheduled for Thursday, August 1 SAN DIEGO , July 11, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m.
- 07/11/2024
|
Top Medical Stocks to Buy for Growth & Performance
- The medical sector is crawling with opportunity as indicated in its representation on the Zacks Rank #1 (Strong Buy) list.
- 07/10/2024
|
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
- PDUFA Target Action Dates in Late December 2024 Highly Selective CRF1 Antagonist is the Potential First New Treatment for CAH in 70 Years SAN DIEGO , July 1, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its two New Drug Applications (NDA) with Priority Review designations for crinecerfont in the treatment of children, adolescents and adults with classic congenital adrenal hyperplasia (CAH). If approved, crinecerfont would be the first new treatment option for CAH in 70 years and a first-in-class therapy, with a novel approach for the treatment of this rare and serious endocrine disorder.
- 07/01/2024
|
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
- Biotech stocks operate under a core ethos. While there's been much talk about financially viable sectors – from tech to cryptocurrencies to even precious metals – when you think about it, nothing is more valuable than one's health.
- 06/17/2024
|
Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
- SAN DIEGO , June 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Diurnal Ltd., a Neurocrine Biosciences company, presented information from its neuroendocrinology pipeline at the Endocrine Society Annual Meeting, ENDO 2024, including primary data just published in The New England Journal of Medicine from its CAHtalyst™ Phase 3 registrational studies of crinecerfont in pediatric and adult patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency.
- 06/03/2024
|
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
- - CAHtalyst™ Pediatric Study Met Primary and Key Secondary Endpoints, with Crinecerfont Treatment Decreasing Androstenedione Levels and Enabling Glucocorticoid Dose Reduction While Maintaining Androstenedione Control - 30% of Crinecerfont Participants Achieved a Physiologic Glucocorticoid Dose at Week 28 while Maintaining Androgen Control versus 0% of Placebo Participants - Favorable Trends in Endpoints Reflecting Supraphysiologic Glucocorticoid Dosing and Androgen Excess - Crinecerfont was Generally Well Tolerated SAN DIEGO , June 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the primary study results from its CAHtalyst™ Pediatric Phase 3 study investigating crinecerfont for the treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency have been published in The New England Journal of Medicine online edition and will appear in a future print issue of the journal. The CAHtalyst Pediatric Phase 3 study met the primary and key secondary endpoints related to androgen reduction (during an initial glucocorticoid-stable period) and glucocorticoid (GC) dose reduction while maintaining androgen control.
- 06/03/2024
|
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
- - CAHtalyst™ Adult Phase 3 Study Met Primary and Important Key Secondary Endpoints, with Crinecerfont Treatment Decreasing Androstenedione Levels and Enabling Glucocorticoid Dose Reduction While Maintaining Androstenedione Control - 62.7% of Crinecerfont Participants Achieved a Physiologic Glucocorticoid Dose while Maintaining Androstenedione Control versus 17.5% of Placebo Participants - Favorable Trends in Endpoints Reflecting Consequences of Supraphysiologic Glucocorticoid Dosing - Crinecerfont was Generally Well Tolerated SAN DIEGO , June 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the primary study results from its CAHtalyst™ Phase 3 study investigating crinecerfont for the treatment of adults ages 18 and older with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency have been published in The New England Journal of Medicine online edition and will appear in a future print issue of the journal. The study met the primary and important key secondary endpoints related to androgen reduction (during an initial glucocorticoid-stable period) and glucocorticoid (GC) dose reduction while maintaining androgen control.
- 06/03/2024
|
Neurocrine Biosciences to Participate at Investor Conferences in June
- Jefferies Global Healthcare Conference on June 5 in New York Goldman Sachs 45th Annual Global Healthcare Conference on June 13 in Miami SAN DIEGO, May 29, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in June. Kevin Gorman, Chief Executive Officer, Kyle Gano, Chief Business Development and Strategy Officer, and Matt Abernethy, Chief Financial Officer will present at the Jefferies Global Healthcare Conference at 2:30 p.m.
- 05/29/2024
|
Neurocrine founder-CEO Gorman to retire in October
- Neurocrine Biosciences CEO Kevin Gorman will retire on Oct. 11 after three decades with the company that he founded and will be succeeded by insider Kyle Gano.
- 05/28/2024
|
Neurocrine Biosciences Announces CEO Succession Plan
- Board of Directors appoints Kyle Gano, Ph.D., Chief Business Development and Strategy Officer, as CEO-elect, effective October 11, 2024 Kevin Gorman, Ph.D.
- 05/28/2024
|
Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024
- New CAHtalyst™ Pediatric and CAHtalyst™ Adult Phase 3 Clinical Study Data in Congenital Adrenal Hyperplasia CAHtalog™ Registry Data Highlighting Impact of Supraphysiologic Glucocorticoid Dosing Phase 2 (CHAMPAIN) Study Data for MRHC vs. Plenadren in Primary Adrenal Insufficiency Long-Term Study Data for MRHC in Adults with CAH SAN DIEGO , May 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its neuroendocrinology pipeline, including new Phase 3 clinical study data from its CAHtalyst™ registrational studies of crinecerfont in pediatric and adult patients with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency and data from its modified-release hydrocortisone (MRHC) studies in primary adrenal insufficiency and CAH.
- 05/28/2024
|
Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules
- SAN DIEGO , May 21, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of data from a post hoc analysis of the Phase 3 KINECT®-4 study of INGREZZA® (valbenazine) capsules in the Journal of Clinical Psychopharmacology . The analysis assessed long-term outcomes relevant to the real-world management of tardive dyskinesia (TD) and demonstrated that nearly all study participants met the threshold for clinically meaningful improvements in TD symptom severity by Week 48.
- 05/21/2024
|
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
- - CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitations of Current CAH Treatment Paradigm in Children, Adolescents and Adults - Phase 2 Study for Modified-Release Hydrocortisone in Adults with Adrenal Insufficiency Demonstrated Participants Achieved Physiological Morning Cortisol Levels after 4 Weeks - Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Adults with CAH Demonstrated Reduction in Median Daily Hydrocortisone Dose and an Increase in Responders at Levels ≤ 25 mg/day SAN DIEGO , May 14, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Diurnal Ltd., a Neurocrine Biosciences company, presented baseline data from the CAHtalyst™ Phase 3 studies of crinecerfont in adult and pediatric patients with congenital adrenal hyperplasia (CAH), and modified-release hydrocortisone (Chronocort®) data for a Phase 2 clinical study (CHAMPAIN) in participants with primary adrenal insufficiency and in a Phase 3 extension study in CAH.
- 05/14/2024
|
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
- CAHtalyst™ Study Baseline Characteristics Highlight the Need for New Treatment Options to Reduce Adrenal Androgens and Supraphysiologic Glucocorticoid Dosing in CAH Adult Patients Comprehensive Literature Review Identified Potential Psychological and Cognitive Impact of High Glucocorticoid Doses in CAH Patients SAN DIEGO , May 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present CAHtalyst™ Adult Phase 3 clinical study baseline characteristics for adults with congenital adrenal hyperplasia (CAH) enrolled in the study, as well as data from a comprehensive literature review assessing the impact of supraphysiologic glucocorticoid (GC) doses on psychiatric disorders and cognition in patients with CAH. The CAHtalyst Adult study baseline data demonstrate the potential long-term consequences of current CAH treatments, with many patients in young adulthood experiencing disorders found more commonly in people decades older, including osteopenia, hypertension and hyperlipidemia.
- 05/09/2024
|
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
- SAN DIEGO , May 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1076986 in healthy adult participants. NBI-1076986 is an investigational, oral, M4 subtype-selective muscarinic acetylcholine receptor antagonist for the potential treatment of movement disorders that was discovered and developed by Neurocrine Biosciences.
- 05/09/2024
|
Nxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
- Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) notes that its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, announced that it has initiated its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117567 in healthy adult participants – see Neurocrine press announcement here .
- 05/09/2024
|
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
- SAN DIEGO , May 8, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117567 in healthy adult participants. NBI-1117567 is an investigational, oral, M1/M4 (M1 preferring) selective muscarinic agonist for the potential treatment of neurological and neuropsychiatric conditions.
- 05/08/2024
|
Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
- SAN DIEGO , May 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pacific Time (2:20 p.m.
- 05/07/2024
|
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
- CAHtalyst™ Pediatric and CAHtalyst™ Adult Baseline Characteristics Data in Congenital Adrenal Hyperplasia Phase 2 (CHAMPAIN) Clinical Study Data for Modified-Release Hydrocortisone (Chronocort®/Efmody®) in Adrenal Insufficiency Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia SAN DIEGO , May 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its neuroendocrinology pipeline, including baseline characteristics data from its CAHtalyst™ Program of crinecerfont in congenital adrenal hyperplasia (CAH), as well as data from its modified-release hydrocortisone studies in primary adrenal insufficiency and CAH, at the European Congress of Endocrinology 2024 meeting in Sweden, May 11–14. Neurocrine Biosciences will be presenting several abstracts and posters at ECE 2024, including: Baseline Characteristics of Children and Adolescents with Classic Congenital Adrenal Hyperplasia Enrolled in CAHtalyst Pediatric, a Phase 3 Study of Crinecerfont, a Corticotropin-Releasing Factor Type 1 Receptor Antagonist May 13; 5:30–6:30pm (Poster# P225) Baseline Characteristics of Adults with Classic Congenital Adrenal Hyperplasia Enrolled in CAHtalyst Adult, a Phase 3 Study of Crinecerfont, a Corticotropin-Releasing Factor Type 1 Receptor Antagonist May 14; 1:40–3:10pm (Poster# P423) CHAMPAIN study: Initial Results from a Phase II Study of Efficacy, Safety and Tolerability of Modified-Release Hydrocortisones: Chronocort® (Efmody®) versus Plenadren, in Primary Adrenal Insufficiency, May 12; 2:00–2:40pm (Rapid Communication #RC3.4) Biochemical Control with Dose Reduction in Chronic Glucocorticoid Therapy over 4 Years: A Phase III Extension Study of Chronocort (Efmody®) in the Treatment of Congenital Adrenal Hyperplasia (CAH) May 12; 2:00–2:40pm (Rapid Communication #RC3.1) Incidence of Adrenal Crisis in Congenital Adrena Hyperplasia (CAH) Patients During a Prospective Monitored Long-Term study of Modified-Release Hydrocortisone (MRHC) Capsules, (Efmody) May 12; 4:20–6:00pm (Poster #P215) Morning Cortisol Levels in Patients with Established Primary Adrenal Insufficiency May 13; 5:30– 6:30pm (Poster #P13) About Congenital Adrenal Hyperplasia Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal hormones which are essential for life.
- 05/07/2024
|
Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring
- Approximately 600,000 people in the United States live with tardive dyskinesia (TD), and about 65% have not yet been diagnosed1-3 The diagnosis rate can be improved by increasing routine TD screenings in people treated with antipsychotic medication4 SAN DIEGO , May 6, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today renewed its commitment to increasing awareness and advancing care for people living with TD during Tardive Dyskinesia Awareness Week, May 5-11. TD is a persistent, involuntary movement disorder associated with the use of antipsychotic medication that may be necessary to treat individuals living with mental illness, such as bipolar disorder, major depressive disorder, schizophrenia and schizoaffective disorder.1,5-7 For seven consecutive years, TD Awareness Week – which occurs each year during Mental Health Awareness Month – has brought together the mental health advocacy community and states across the country to recognize the approximately 600,000 people in the U.S. living with TD.1,2 This year, Neurocrine is joining participants of TD Awareness Week to conduct initiatives nationwide to decrease stigma, improve recognition and increase routine screenings, diagnosis and awareness of appropriate treatment of TD.
- 05/06/2024
|
Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam
- Nvidia stock along with four other leading stocks are in or near buy areas as the market rally appears to be picking up steam.
- 05/04/2024
|
Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
- CAHtalyst™ Pediatric Study Baseline Characteristics Data Highlight Need for Novel Treatments in Children and Adolescents with Congenital Adrenal Hyperplasia (CAH) CAHtalog™ Registry Data of Glucocorticoid Treatment Patterns in Pediatric and Adult Patients Illustrates the Challenges of Long-Term CAH Management SAN DIEGO , May 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today presented the CAHtalyst™ Pediatric Phase 3 clinical study baseline characteristics data for children and adolescents with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency enrolled in the study, along with CAHtalog™ Registry data assessing glucocorticoid treatment patterns in pediatric and adult patients with CAH. These data demonstrate the limitations of current CAH treatment approaches in pediatric patients, comorbidities associated with the condition and/or current treatment, including obesity, advanced bone age, and early puberty, and the difficulty in managing the disease effectively as CAH patients age into adults.
- 05/03/2024
|
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say
- Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 05/01/2024
|
Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
- Neurocrine Biosciences (NBIX) came out with quarterly earnings of $0.42 per share, missing the Zacks Consensus Estimate of $1.04 per share. This compares to loss of $0.79 per share a year ago.
- 05/01/2024
|
Neurocrine Biosciences Reports First Quarter 2024 Financial Results
- INGREZZA® (valbenazine) First Quarter Net Product Sales of $506 Million Representing 23% Year-Over-Year Growth INGREZZA® SPRINKLE (valbenazine) Capsules Approved by the U.S. FDA Crinecerfont New Drug Applications for the Treatment of Congenital Adrenal Hyperplasia Submitted to the U.S. FDA Positive Phase 2 Top-Line Data for NBI-1065845, a Potential First-In-Class AMPA Positive Allosteric Modulator, in Adults with Major Depressive Disorder SAN DIEGO , May 1, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2024 and provided an update on its 2024 financial guidance. "Significant unmet need still exists for the many patients living with tardive dyskinesia as exemplified with INGREZZA's first quarter year-over-year growth of 23%," said Kevin Gorman, Ph.D.
- 05/01/2024
|
FDA approves Neurocrine Biosciences' Huntington's disease drug
- The U.S. Food and Drug Administration (FDA) has approved granule formulation of Neurocrine Biosciences' drug to treat movement disorders associated with Huntington's disease, the company said on Tuesday.
- 04/30/2024
|
Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules
- SAN DIEGO , April 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved INGREZZA® SPRINKLE (valbenazine) capsules, a new oral granules formulation of INGREZZA® (valbenazine) capsules prescribed for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease.1 INGREZZA SPRINKLE provides an alternative administration option for those who experience dysphagia or have difficulty swallowing. Like the original formulation of INGREZZA capsules, INGREZZA SPRINKLE offers simple dosing that's always one capsule, once daily with no complex titration.1 INGREZZA is the only selective vesicular monoamine transporter 2 (VMAT2) inhibitor that offers three effective dosages (40 mg, 60 mg and 80 mg) that can be adjusted by the healthcare provider based on patient response and tolerability.1 INGREZZA SPRINKLE offers the same dosage strengths, and the contents of the capsules can be easily sprinkled on soft food for oral administration.
- 04/30/2024
|
Curious about Neurocrine (NBIX) Q1 Performance? Explore Wall Street Estimates for Key Metrics
- Beyond analysts' top -and-bottom-line estimates for Neurocrine (NBIX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
- 04/30/2024
|
Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
- Neurocrine Biosciences, Inc. achieved positive results achieved from phase 2 SAVITRI study using NBI-1065845 for the treatment of patients with Major Depressive Disorder. NBI-1065845 may offer some advantages over currently approved MDD therapies, such as Auvelity from Axsome Therapeutics and Spravato from Johnson & Johnson. The global Major Depressive Disorder treatment market is expected to reach $14.96 billion by 2032.
- 04/25/2024
|
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
- Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/24/2024
|
Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
- WHAT THE C@H?! provides a platform for the congenital adrenal hyperplasia (CAH) community to find educational information, share experiences and learn about current research.
- 04/24/2024
|
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
- SAVITRI™ Study Met Primary Endpoint with Statistically Significant Reduction in Montgomery Åsberg Depression Rating Scale ( MADRS) Total Score at Day 28 Met Key Secondary Endpoints, Including Statistically Significant Reduction in MADRS Score at Day 56 NBI-1065845 Was Generally Well-Tolerated SAN DIEGO , April 23, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced positive topline data for its Phase 2 SAVITRI™ study. This randomized, double-blind, placebo-controlled dose-finding study assessed the efficacy and safety of NBI-1065845 in adult subjects with major depressive disorder (MDD).
- 04/23/2024
|
Three top U.S. biotech stocks to buy in April
- “Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024.
- 03/28/2024
|
S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind
- S&P 500 stocks DexCom, Blackstone and Royal Caribbean lead five stocks around buy points after Fed chief Jerome Powell helped buoy markets.
- 03/23/2024
|
AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base
- Artificial intelligence plays HubSpot and Arista Networks are among five stocks near buy points with big market news on tap.
- 03/16/2024
|
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
- Biotech stocks have always been high-risk and high-reward, with the futures and fortunes of companies often decided with a single successful drug trial or Federal Drug Administration (FDA) approval. The right company can yield extravagant returns for the lucky or prudent investor.
- 03/06/2024
|
Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside
- Neurocrine Biosciences' shares have sold off post-earnings on concerns about its near-term opex spending and slowing growth for lead drug Ingrezza. Higher-than-expected opex spending includes targeted spending to grow the Ingrezza business (Huntington's chorea and long-term care facilities) and prepare the market for the eventual crinecerfont launch. Neurocrine has a number of Phase II read-outs coming in 2024, and while these are high-risk programs, compelling efficacy data could drive meaningful share price upside.
- 02/10/2024
|
Neurocrine (NBIX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
- While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 02/07/2024
|
AMLX vs. NBIX: Which Stock Should Value Investors Buy Now?
- Investors with an interest in Medical - Drugs stocks have likely encountered both Amylyx Pharmaceuticals, Inc. (AMLX) and Neurocrine Biosciences (NBIX). But which of these two companies is the best option for those looking for undervalued stocks?
- 01/31/2024
|
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
- Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/31/2024
|
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results
- Conference Call and Webcast Scheduled for Wednesday, February 7 SAN DIEGO , Jan. 17, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2023 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m.
- 01/17/2024
|
Wedbush's Laura Chico talks biotech investing in 2024
- Laura Chico, Wedbush Biotech Analyst, joins 'Closing Bell Overtime' to talk investing in biotech.
- 12/26/2023
|
Neurocrine (NBIX) Soars 6.0%: Is Further Upside Left in the Stock?
- Neurocrine (NBIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- 12/26/2023
|
3 Stocks at the Forefront of Medical Innovation
- Innovation in the medical world is undoubtedly a fundamental pillar in the development of humanity. There are great companies within the biotech sector doing wonderful work, research, and developments, not only to attack important diseases but also to prevent them.
- 12/25/2023
|
The 3 Most Undervalued Biotech Stocks to Buy in December
- As technology advances in our era, biotechnology is not far behind. Modern day medical advancements are impressive, and the company's making these strides have incredible results to show for it.
- 12/15/2023
|
Neurocrine Biosciences: Fear Not The IRA
- Neurocrine Biosciences' stock has been stagnant due to a lack of appreciation for positive updates and the modest mid-stage pipeline setbacks. The company recently settled with generic filers, ensuring no generic launch of Ingrezza until 2038 and highlighting the strength of its intellectual property. The concerns over the impact of the Inflation Reduction Act on Ingrezza seem overblown.
- 11/30/2023
|
Neurocrine Biosciences shares drop as trial failures may ‘stunt momentum,' analysts say
- Neurocrine Biosciences Inc. shares NBIX, -2.81% fell 4.7% premarket on Friday after the company on Thursday announced two clinical trial failures.
- 11/10/2023
|
3 Biotech Moonshots to Bet on the Future of Health
- Biotech stocks are incredibly risky but can provide investors with huge returns since insurers in the U.S. will pay tremendous amounts for successful treatments. In the last few months in particular, the potential risks of biotech stocks have increased only a bit while their possible returns have increased tremendously.
- 11/06/2023
|
Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Call Transcript
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q3 2023 Earnings Conference Call October 31, 2023 8:00 AM ET Company Participants Todd Tushla - Vice President, Investor Relations Kevin Gorman - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eiry Roberts - Chief Medical Officer Eric Benevich - Chief Commercial Officer Kyle Gano - Chief Business Development and Strategy Officer Conference Call Participants Phil Nadeau - TD Cowen Chris Shibutani - Goldman Sachs Paul Matteis - Stifel Tazeen Ahmad - Bank of America Brian Abrahams - BRC Capital Markets Josh Schimmer - Cantor Leon Wang - Barclays Anupam Rama - JPMorgan Jay Olson - Oppenheimer Marc Goodman - Leerink Partners Michael Riad - Morgan Stanley Myles Minter - William Blair Yatin Suneja - Guggenheim Partners Laura Chico - Wedbush Securities Sumant Kulkarni - Canaccord David Amsellem - Piper Sandler Ash Verma - UBS Ami Fadia - Needham Uy Ear - Mizuho Conor MacKay - BMO Capital Markets Operator Good day, everyone. And welcome to the Neurocrine Biosciences Reports third quarter results.
- 10/31/2023
|
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
- Neurocrine Biosciences (NBIX) came out with quarterly earnings of $0.82 per share, missing the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.69 per share a year ago.
- 10/31/2023
|
Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To Reward The Success
- Neurocrine Biosciences has reported very positive Phase III results for crinecerfont in adult and pediatric congenital adrenal hyperplasia. The adult study showed that 63% of patients on crinecerfont were able to reduce their steroid usage to physiological replacement levels, and 30% of children reached this threshold. The market has reacted with muted enthusiasm, possibly due to the limited data provided and a potentially challenging commercial launch.
- 10/11/2023
|
Bet on These 4 Top-Ranked Liquid Stocks for Robust Returns
- Here are four top-performing liquid stocks, Neurocrine Biosciences (NBIX), GigaCloud Technology (GCT), NVIDIA (NVDA) and Sprinklr (CXM), which investors can add to their portfolio for robust returns.
- 10/09/2023
|
Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why
- Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
- 10/03/2023
|
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
- 2023 Wells Fargo Healthcare Conference on September 7 in Boston Morgan Stanley 21st Annual Global Healthcare Conference on September 12 in New York SAN DIEGO , Aug. 31, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in September. Kyle Gano, Chief Business Development and Strategy Officer, and Todd Tushla, Vice President of Investor Relations, will present at the 2023 Wells Fargo Healthcare Conference at 3:45 p.m.
- 08/31/2023
|
Neurocrine Needs A Meaningful Clinical Win To Break Out, And Crinecerfont Could Do It
- Neurocrine Biosciences needs a clinical win after years of disappointing results and stagnant stock performance. The upcoming Phase III data on crinecerfont, a treatment for congenital adrenal hyperplasia, is highly significant to sentiment, and earlier data read-outs do offer some reasons for bullishness. I believe Neurocrine shares should trade in the mid-$120s; success with crinecerfont can drive a fair value in the $130's, though failure would drive fair value to the $105 range.
- 08/25/2023
|
Neurocrine Biosciences price target raised at Oppenheimer after FDA approves movement disorder treatment
- Neurocrine Biosciences Inc. NBIX, +2.55% said Friday that the U.S. Food and Drug Administration has approved Ingrezza for treatment of an involuntary movement disorder linked with Huntington's disease, prompting analysts at Oppenheimer to boost their price target on the shares. “Ingrezza could become a pipeline-in-a-product,” based on additional indications beyond the movement disorder, called chorea, the Oppenheimer analysts wrote in a note Sunday, raising their price target on the stock to $154, from $150 previously.
- 08/21/2023
|
Deerfield Management Company, L.P.
- Deerfield Management Company, L.P. (Series C), a renowned investment firm, recently made a significant addition to its portfolio.
- 08/01/2023
|
Neurocrine (NBIX) Reports Q2 Earnings: What Key Metrics Have to Say
- Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 08/01/2023
|
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
- Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/25/2023
|
Neurocrine Biosciences: Multiple 2023 Catalysts Makes It A Must-Watch
- Neurocrine Biosciences: Multiple 2023 Catalysts Makes It A Must-Watch.
- 04/24/2023
|
3 Pharma Stocks That Could See a Surge in Demand in 2023
- As 2023 unfolds, the pharmaceutical space is blossoming with new opportunities, sparking curiosity for those looking to buy some pharma stocks. With the iShares Biotechnology ETF (NASDAQ: IBB ) ticking upward, for the most part, this year, investors who dive into pharma stocks need to capitalize on the sector's positive momentum.
- 04/24/2023
|
Neurocrine Biosciences: Today's Best Near-Term Cap-Gain Biotech Developer Prospect
- Neurocrine Biosciences: Today's Best Near-Term Cap-Gain Biotech Developer Prospect.
- 04/22/2023
|
3 Growth Stocks That Could Disrupt the Healthcare Industry
- Healthcare growth stocks are often sought out by investors looking for market disruptors. That's because these stocks can potentially deliver high revenue growth, earnings, and stock price.
- 03/13/2023
|
Neurocrine Biosciences to Participate at Investor Conferences in March
- Barclays Global Healthcare Conference on March 15 in Miami Jefferies Biotech on the Bay Summit on March 16 in Miami SAN DIEGO , March 8, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the Barclays Global Healthcare Conference at 10:45 a.m.
- 03/08/2023
|
NBIX Stock: 4.55% Decrease Explanation
- The stock price of Neurocrine Biosciences (NASDAQ: NBIX) fell by 4.55% in the most recent trading session. This is why.
- 02/07/2023
|
Neurocrine Biosciences, Inc. (NBIX) Q4 2022 Earnings Call Transcript
- Start Time: 08:00 January 1, 0000 9:02 AM ET Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q4 2022 Earnings Conference Call February 06, 2023, 08:00 AM ET Company Participants Kevin Gorman - CEO Matt Abernethy - CFO Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer Kyle Gano - Chief Business Development and Strategy Officer Todd Tushla - VP of IR Conference Call Participants Paul Matteis - Stifel Neena Bitritto-Garg - Citi Tazeen Ahmad - Bank of America Brian Skorney - Baird Phil Nadeau - Cowen & Company Chris Shibutani - Goldman Sachs Carter Gould - Barclays Myles Minter - William Blair Brian Abrahams - RBC Capital Markets Jay Olson - Oppenheimer Charles Duncan - Cantor Fitzgerald Laura Chico - Wedbush Securities Marc Goodman - SVB Securities Ashwani Verma - UBS David Amsellem - Piper Sandler Evan Seigerman - BMO Capital Markets Ami Fadia - Needham Yatin Suneja - Guggenheim Partners Sumant Kulkarni - Canaccord Genuity Mohit Bansal - Wells Fargo Operator Good day, everyone, and welcome to today's Neurocrine Biosciences Reports Fourth Quarter and Year End Results. At this time, all participants are in a listen-only mode.
- 02/06/2023
|
Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates
- Neurocrine (NBIX) delivered earnings and revenue surprises of -23.48% and 0.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/06/2023
|
Neurocrine Bio Tops Fourth-Quarter Views As Profit Skyrockets
- Neurocrine Biosciences reported strong fourth-quarter profit growth on Monday and beat fourth-quarter estimates. But NBIX stock was flat.
- 02/06/2023
|
Neurocrine Biosciences: Stencil In These Important Dates
- Expect strong Neurocrine Biosciences, Inc. Q4 results on February 6, 2023. Two important pipeline results regarding congenital adrenal hyperplasia and focal onset seizures will be coming this February.
- 01/25/2023
|
Neurocrine Biosciences: Scope For Valuation Upside With Ingrezza Numbers
- After a strong performance in H2 FY22, Neurocrine Biosciences saw a sharp reversal into the new year. The question is, does this present an opportunity to buy or not?
- 01/24/2023
|
Voyager Therapeutics stock soars, analysts raise price target on new collaboration with Neurocrine Biosciences to advance its gene therapies
- Voyager Therapeutics Inc (NASDAQ:VYGR) shares have jumped on the news that the biotechnology company has entered into a strategic collaboration with Neurocrine Biosciences (NASDAQ:NBIX) Inc to advance multiple gene therapies for the treatment of neurological diseases. The company's stock was up 15.7% at US$8.05 just before noon on Monday, while Neurocrine shares had shed 9.3% to US$111.62.
- 01/09/2023
|
6 Favorite Biotech Bets For 2023
- Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation's leading newsletter advisors. This year's report is no exception; here's a six-pack of favorite biotech ideas for the coming year.
- 01/09/2023
|
Voyager, Neurocrine ink gene-therapy deal
- Shares of Voyager Therapeutics Inc. VYGR, +10.65% rallied 35% in premarket trading on Monday after the company announced a deal with Neurocrine Biosciences Inc. NBIX, +0.06% to develop and commercialize gene therapies, including one that is being tested as a treatment for Parkinson's disease. Neurocrine will make a $175 million upfront payment, including a $39 million equity investment, with up to $1.5 billion in potential milestones.
- 01/09/2023
|
Oil Firm Eyeing 3,755% Q4 Growth Leads 24 Fastest-Growing Stocks
- With analysts expecting a whopping 3,755% Q4 growth, H.F. Sinclair leads this list of 24 of today's fastest-growing stocks.
- 12/01/2022
|
Hot Biotech Stocks Rise Into Leadership; Pass Buy Points Or Build Bases
- Top biotech stocks surge within the IBD 50. Some pass buy points while others build bases.
- 11/25/2022
|
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday's high of $125.99. It is forming a bullish channel.
- 11/11/2022
|
Three Stocks Rise, Watchlist Grows With Midterm Elections, Fed In Focus
- As Leaderboard stocks Enphase Energy, Wingstop and Cheniere Energy navigate Fed rate hikes, all eyes now turn to the midterm elections. The post Three Stocks Rise, Watchlist Grows With Midterm Elections, Fed In Focus appeared first on Investor's Business Daily.
- 11/07/2022
|
3 Reasons Growth Investors Will Love Neurocrine (NBIX)
- Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.
- 11/04/2022
|
Neurocrine Biosciences, Inc. (NBIX) Q3 2022 Earnings Call Transcript
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q3 2022 Earnings Conference Call November 1, 2022 8:00 AM ET Company Participants Todd Tushla - VP of IR Kevin Gorman - CEO Matt Abernethy - CFO Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer Kyle Gano - Chief Business Development & Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Paul Matteis - Stifel Phil Nadeau - Cowen & Company Neena Bitritto-Garg - Citi Anupam Rama - JPMorgan Brian Abrahams - RBC Capital Markets Carter Gould - Barclays Chris Shibutani - Goldman Sachs Myles Minter - William Blair Brian Skorney - Baird Laura Chico - Wedbush Ashish Sharma - UBS Jeff Hung - Morgan Stanley Jay Olson - Oppenheimer Marc Goodman - SVB David Amsellem - Piper Sandler Uy Ear - Mizuho Securities Conor MacKay - BMO Capital Markets Yatin Suneja - Guggenheim Partners Mohit Bansal - Wells Fargo Sumant Kulkarni - Canaccord Genuity Operator Good day, everyone. And welcome to today's Neurocrine Biosciences Reports Third Quarter Results.
- 11/01/2022
|
Neurocrine Biosciences (NBIX) Q3 Earnings Lag Estimates
- Neurocrine (NBIX) delivered earnings and revenue surprises of -17.86% and 2.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/01/2022
|
Blazing Hot Neurocrine Biosciences, With 35% Run This Year, Extends Breakout On Quarterly Beat
- Neurocrine Biosciences beat third-quarter forecasts and raised its Ingrezza outlook for 2022, leading NBIX stock to jump Tuesday. The post Blazing Hot Neurocrine Biosciences, With 35% Run This Year, Extends Breakout On Quarterly Beat appeared first on Investor's Business Daily.
- 11/01/2022
|
Vertex Among 9 Stocks To Watch In Struggling Market
- As the market indexes work through a downturn, Vertex is among nine stocks to watch showing relative strength. The post Vertex Among 9 Stocks To Watch In Struggling Market appeared first on Investor's Business Daily.
- 10/03/2022
|
S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market
- S&P 500 giant Eli Lilly leads five medical stocks setting up and showing relative strength in the ongoing bear market. The post S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market appeared first on Investor's Business Daily.
- 09/24/2022
|
S&P 500 Dividend Standout Leads 5 Resilient Stocks Near Buy Points As Fed Looms
- S&P 500 dividend standout Devon Energy leads this weekend's watch list of stocks near buy points in a tough market. The post S&P 500 Dividend Standout Leads 5 Resilient Stocks Near Buy Points As Fed Looms appeared first on Investor's Business Daily.
- 09/17/2022
|
Neurocrine Biosciences to Present Study Findings on Evolving Tardive Dyskinesia Education Needs of Physicians at the 2022 MDS International Congress
- SAN DIEGO , Sept. 15, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the presentation of survey findings demonstrating the need for education on supportive evidence regarding best approaches to managing tardive dyskinesia (TD) symptoms while maintaining control of the underlying psychiatric disorder.
- 09/15/2022
|
15 Stocks Billionaire Investors Agree It's Smart To Buy Now
- Big investors are famous for breaking rank from the S&P 500 crowd. So when you see a few agreeing on a stock, it's worth paying attention.
- 09/12/2022
|
3 Growth Stocks That Are Crushing It This Year
- These three biotech companies have bucked the trend of declining shares prices in their sector.
- 09/10/2022
|
Neurocrine Biosciences to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
- SAN DIEGO , Sept. 6, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 20th Annual Global Healthcare Conference at 10:35 a.m.
- 09/06/2022
|
Neurocrine Leads 5 Stocks To Watch In Sickly Market
- Neurocrine Biosciences leads five medical stocks near key support levels as the health care sector shows resilience in a sickly market. The post Neurocrine Leads 5 Stocks To Watch In Sickly Market appeared first on Investor's Business Daily.
- 09/03/2022
|
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
- The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
- 08/31/2022
|
Neurocrine Biosciences Goes Dumpster-Diving To Accelerate Its International Business Development
- Neurocrine is acquiring beaten-down Diurnal Group for $57M, primarily to accelerate its ex-U.S. business development. Diurnal has a pipeline of hormone-based therapeutics, including Efmody (commercialized in Europe), but the pipeline is likely secondary to the clinical/commercial infrastructure Diurnal offers.
- 08/31/2022
|
Neurocrine Is Seeing A Very Welcome Pick Up In Ingrezza, But Pipeline Catalysts Are Thin
- Neurocrine saw a meaningful improvement in Ingrezza sales, with revenue growing 32% and beating sell-side expectations by 8%. Management announced that '104 failed to show meaningful efficacy in a Phase II proof-of-concept study, and the company has few near-term clinical catalysts.
- 08/08/2022
|
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q2 2022 Results - Earnings Call Transcript
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Todd Tushla - Vice President of Investor Relations Kevin Gorman - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eiry Roberts - Chief Medical Officer Eric Benevich - Chief Commercial Officer Kyle Gano - Chief Business Development and Strategy Officer Conference Call Participants Phil Nadeau - Cowen & Company Leonid Timashev - RBC Capital Markets Paul Matteis - Stifel Tazeen Ahmad - Bank of America Neena Bitritto-Garg - Citi Jay Olson - Oppenheimer Carter Gould - Barclays Anupam Rama - JPMorgan Brian Skorney - Baird Chris Shibutani - Goldman Sachs Myles Minter - William Blair Danielle Brill - Raymond James Laura Chico - Wedbush Marc Goodman - SVB David Amsellem - Piper Sandler Yatin Suneja - Guggenheim Partners Operator Good day, everyone. And welcome to today's Neurocrine Biosciences Reports Second Quarter Results [Operator Instructions].
- 08/04/2022
|
Neurocrine Biosciences (NBIX) Reports Q2 Loss, Tops Revenue Estimates
- Neurocrine (NBIX) delivered earnings and revenue surprises of -132.14% and 11.03%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2022
|
The Make-Or-Break Moment Is Here For Highly Rated Neurocrine Biosciences
- It's make-or-break time for Neurocrine Biosciences' essential tremors treatment, analysts say, as NBIX stock trends sideways. The post The Make-Or-Break Moment Is Here For Highly Rated Neurocrine Biosciences appeared first on Investor's Business Daily.
- 07/29/2022
|
10 Best Low-Volatility Stocks to Buy Now
- The stock market is suffering a turbulent 2022 so far – and with inflation still running at a 40-year high, the Federal Reserve locked in a significant rate-hiking cycle and midterm elections just months away, it's likely the volatility is going to remain for the time being. Investors looking for a smoother market ride should consider buying low-volatility stocks as a way to manage risk.
- 07/25/2022
|
Better Ingrezza Sales And A Clinical Trial Read-Out Could Reignite Neurocrine Shares
- Neurocrine should soon release Phase II data on NBI-827104, and a positive read-out on a largely overlooked drug today could add 5% to 10% to NBIX's fair value. Between the expansion of the sales force and new marketing initiatives, Neurocrine is looking to reignite sales momentum in Ingrezza, a drug that I still believe has meaningful growth potential.
- 07/18/2022
|
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2022 Financial Results
- Conference Call and Webcast Scheduled for Thursday, August 4 SAN DIEGO , July 14, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter 2022 financial results after the Nasdaq market closes on Thursday, August 4, 2022. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 p.m.
- 07/14/2022
|
Neurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
- SAN DIEGO , June 8, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 43rd Annual Global Healthcare Conference at 10:40 a.m. Pacific Time (1:40 p.m.
- 06/08/2022
|
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q1 2022 Results - Earnings Call Transcript
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q1 2022 Earnings Conference Call May 4, 2022 8:00 AM ET Company Participants Todd Tushla - VP, IR Kevin Gorman - CEO & Director Matthew Abernethy - CFO Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer Kyle Gano - Chief Business Development and Strategy Officer Conference Call Participants Paul Matteis - Stifel, Nicolaus & Company Brian Skorney - Robert W. Baird & Co. Carter Gould - Barclays Bank Neena Bitritto-Garg - Citigroup Tazeen Ahmad - Bank of America Merrill Lynch Joshua Schimmer - Evercore ISI Anupam Rama - JPMorgan Chase & Co. Charles Duncan - Cantor Fitzgerald & Co. Philip Nadeau - Cowen and Company Jeff Hung - Morgan Stanley Chris Shibutani - Goldman Sachs Group Jay Olson - Oppenheimer Laura Chico - Wedbush Securities Marc Goodman - SVB Leerink Vamil Divan - Mizuho Securities Myles Minter - William Blair & Company Yatin Suneja - Guggenheim Securities Operator Good day, everyone, and welcome to today's Neurocrine Biosciences Reports First Quarter Results.
- 05/04/2022
|
Neurocrine Biosciences (NBIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/27/2022
|
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2022 Financial Results
- Conference Call and Webcast Scheduled for Wednesday, May 4 SAN DIEGO , April 13, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2022 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m.
- 04/13/2022
|
Neurocrine Biosciences to Present Data on Treatment Patterns and Unmet Needs in Adult and Pediatric Patients Living with Classic Congenital Adrenal Hyperplasia at AMCP 2022
- SAN DIEGO , March 28, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data on treatment patterns and unmet needs in adult and pediatric patients with classic congenital adrenal hyperplasia (CAH) at the Academy of Managed Care Pharmacy (AMCP) 2022 annual meeting in Chicago on March 29–April 1. The three studies being presented evaluate the treatment patterns, healthcare-related costs, medication preferences, and unmet needs of patients with classic CAH.
- 03/28/2022
|
Bear of the Day: Neurocrine Biosciences (NBIX)
- Strong growth for Ingrezza meets company investment in the pipeline, sparking lowered EPS estimates
- 02/28/2022
|
Neurocrine Biosciences Looking At A Year Of Heavy Lifting
- Neurocrine exited 2021 with high single-digit qoq growth in Ingrezza prescriptions, but management is investing even more SG&A resources into recharging sales growth and momentum.
- 02/15/2022
|
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q4 2021 Results - Earnings Call Transcript
- Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q4 2021 Results - Earnings Call Transcript
- 02/11/2022
|
Why Neurocrine Biosciences Are Trading Higher Today?
- Neurocrine Biosciences Inc (NASDAQ: NBIX) reported Q4 Ingrezza sales of $301 million, +25% Y/Y, with total prescriptions up 32% Overall sales increased $312.0 million 26%, missing the consensus of $316.79 million.
- 02/11/2022
|
Neurocrine Biosciences (NBIX) Reports Q4 Loss, Misses Revenue Estimates
- Neurocrine (NBIX) delivered earnings and revenue surprises of -113.11% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/11/2022
|
Analysts Estimate Neurocrine Biosciences (NBIX) to Report a Decline in Earnings: What to Look Out for
- Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/04/2022
|
Neurocrine Biosciences: Taking Advantage Of A Shrinking Share Price Ahead Of Projected Growth
- I have admired Neurocrine's clinical prowess and the prospects of their flagship product, INGREZZA. The company's continued growth has kept the ticker on my watch list and the 2021 sell-off has brought the valuation down to a more acceptable level.
- 01/30/2022
|
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2021 Financial Results
- SAN DIEGO, Jan. 25, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2021 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m.
- 01/25/2022
|
Neurocrine's Ingrezza Meets Primary Goal In Phase 3 Study In Patients With Involuntary Muscle Movement
- Neurocrine Biosciences Inc (NASDAQ: NBIX) revealed topline data from its Phase 3 KINECT-HD study evaluating Ingrezza (valbenazine) for chorea associated with Huntington's disease (HD). The selective vesicular monoamine transporter 2 (VMAT2) inhibitor is being investigated as a once-daily treatment in adult patients.
- 12/08/2021
|
Neurocrine Biosciences Gets Promising Drugs in Licensing Deal
- Following disappointing third-quarter earnings, Neurocrine Biosciences, Inc. ( NBIX , Financial) shareholders were looking for a shred of good news that could boost the price of the San-Diego-based biopharma, which is trading near its 52-week low.
- 11/24/2021
|
Neurocrine Biosciences: Generic Drug Stock Seen As Underpriced By Market-Makers For Near Gains
- Sharp down days are when to look for surprise values in underpriced stocks. Not the story issues being ballyhooed by touts and the media - everyone knows them. The hidden values are ones found by experienced professional researchers who know the details of industry group issues and their special strengths.
- 11/08/2021
|
Why Neurocrine Biosciences Shares Fell Nearly 10% Today
- Investors have grown weary of unpredictable profitability and unexpected expenses.
- 11/02/2021
|
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2021 Results - Earnings Call Transcript
- Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2021 Results - Earnings Call Transcript
- 11/01/2021
|
Neurocrine Biosciences (NBIX) Lags Q3 Earnings Estimates
- Neurocrine (NBIX) delivered earnings and revenue surprises of -54.90% and 0.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/01/2021
|
Neurocrine Biosciences: Q3 Earnings Insights
- Neurocrine Biosciences (NASDAQ:NBIX) reported its Q3 earnings results on Monday, November 1, 2021 at 04:01 PM. Here's what investors need to know about the announcement.
- 11/01/2021
|
Neurocrine, ACADIA: Fast Growing Health Care Stocks That Are Underperforming
- Our theme of Out Of Favor Health Care Stocks includes biotech and pharma names that are seeing a disconnect between their recent financial performance and recent stock price returns. The theme remains down by about 35% year-to-date, compared to the S&P 500 which is up by a solid 21%.
- 10/26/2021
|
Neurocrine Biosciences to Present ONGENTYS® (opicapone) and INGREZZA® (valbenazine) Data at the American Neurological Association 2021 Virtual Annual Meeting
- SAN DIEGO, Oct. 16, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its movement disorder treatments for Parkinson's disease and tardive dyskinesia (TD) at the American Neurological Association (ANA) 2021 Virtual Annual Meeting being held October 17–19, 2021. Neurocrine Biosciences will present new post-hoc analysis of pooled data from the ONGENTYS® (opicapone) BIPARK-1 and BIPARK-2 Phase 3 studies evaluating nighttime "off" episodes in people with Parkinson's disease and motor fluctuations.
- 10/16/2021
|
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2021 Financial Results
- SAN DIEGO, Oct. 11, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report third quarter 2021 financial results after the Nasdaq market closes on Monday, November 1, 2021. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 p.m.
- 10/11/2021
|
Neurocrine Biosciences Expands Monumental Moments™ Program With World-Renowned Artist Jorge Rodriguez-Gerada to Raise Mental Health Awareness and Honor Those Impacted by the Pandemic
- SAN DIEGO, Oct. 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced a collaboration with renowned contemporary artist, Jorge Rodriguez-Gerada best known for his urban large-scale mural portraits, to create an original piece of art called Monumental Moments - The Hug, a nearly 10-foot-tall bronze sculpture that immortalizes the monumental times everyone has experienced during the pandemic and celebrates the human spirit, the resilience of the mental health community and all those who have been impacted by the pandemic. Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8950551-neurocrine-biosciences-expands-monumental-moments-program-with-jorge-rodriguez-gerada/ Inspired by the hundreds of stories shared on MonumentalMoments.com over the past year, Monumental Moments - The Hug was unveiled on Thursday, October 7, to coincide with Mental Illness Awareness Week (October 3-9) and ahead of World Mental Health Day (October 10) at New York City's iconic Lincoln Center.
- 10/08/2021
|
Neurocrine Biosciences to Present New INGREZZA® (valbenazine) and ONGENTYS® (opicapone) Data at the MDS Virtual Congress 2021
- SAN DIEGO, Sept. 10, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data from its movement disorder treatments for tardive dyskinesia (TD) and Parkinson's disease at the International Parkinson and Movement Disorder Society's (MDS) Virtual Congress 2021 being held September 17–22, 2021.
- 09/10/2021
|
Neurocrine Biosciences Trading Near Its 52-Week Low As Delta Threatens The Ingrezza Rebound
- Neurocrine Biosciences Trading Near Its 52-Week Low As Delta Threatens The Ingrezza Rebound
- 08/11/2021
|
Neurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD Study Evaluating Valbenazine for Chorea in Huntington Disease
- SAN DIEGO, Aug. 5, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), in collaboration with the Huntington Study Group, today announced the completion of patient enrollment for its Phase 3 (KINECT-HD) clinical study evaluating the efficacy, safety and tolerability of valbenazine, a selective, orally active vesicular monoamine transporter 2 (VMAT2) inhibitor being investigated as a once-daily treatment in adults with chorea in Huntington disease. A top-line data readout of the clinical study results is anticipated by the end of 2021.
- 08/05/2021
|
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q2 2021 Results - Earnings Call Transcript
- Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q2 2021 Results - Earnings Call Transcript
- 08/03/2021
|
Neurocrine Biosciences (NBIX) Q2 Earnings Miss Estimates
- Neurocrine (NBIX) delivered earnings and revenue surprises of -17.31% and 5.26%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/03/2021
|
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results
- SAN DIEGO, July 19, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter 2021 financial results after the Nasdaq market closes on Tuesday, August 3, 2021. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 p.m.
- 07/19/2021
|
Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference
- SAN DIEGO, July 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Kyle Gano, Chief Business Development and Strategy Officer, will participate in a neuropsychology-focused panel discussion at the William Blair Biotech Focus Conference at 12:00 p.m. Eastern Time on Thursday July 15, 2021.
- 07/08/2021
|
Sarepta, Vertex, Neurocrine: There's Deep Value In These Beaten Down Healthcare Stocks
- Our theme of Out Of Favor Health Care Stocks includes healthcare and pharma names that are seeing a disconnect between their financial performance and stock price returns. Specifically, the theme filters for healthcare companies that have grown revenue by at least 50% over the last three years.
- 07/01/2021
|
BofA Securities Makes Big Summer Changes to US 1 List of Top Stock Picks
- With the second quarter of 2021 all but over and the latter half of 2021 right around the corner, many of the top companies we follow on Wall Street are making some changes to their lists of high-conviction stock picks for clients.
- 06/30/2021
|
Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment
- Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment.
- 06/02/2021
|
Neurocrine Biosciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
- SAN DIEGO, June 1, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference at 1:20 p.m. Eastern Time on Tuesday, June 8, 2021.
- 06/01/2021
|
Neurocrine Biosciences: Pandemic Pressures And Few Pipeline Catalysts Continue To Weigh On NBIX
- Neurocrine once again posted disappointing Ingrezza sales, and while the post-pandemic reopening should help, it likely won't be an immediate recovery. Management is advancing a broad pipeline of high-risk/high-reward candidates into Phase II studies for a range of movement and psychiatric disorders.
- 05/26/2021
|
Neurocrine Biosciences to Present at the 2021 RBC Global Healthcare Conference
- SAN DIEGO, May 11, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 2021 RBC Capital Markets Healthcare Conference at 10:55 a.m. Eastern Time on Tuesday May 18, 2021.
- 05/11/2021
|
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q1 2021 Results - Earnings Call Transcript
- Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q1 2021 Results - Earnings Call Transcript
- 05/05/2021
|
Neurocrine Biosciences (NBIX) Q1 Earnings and Revenues Miss Estimates
- Neurocrine (NBIX) delivered earnings and revenue surprises of -29.79% and -4.52%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2021
|
Neurocrine Biosciences Reports First Quarter 2021 Financial Results
- SAN DIEGO, May 5, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2021 and provided revised full-year 2021 financial expense guidance. "Our first quarter results reflect a lower than normal refill rate per patient due to the typical seasonal payor dynamics for INGREZZA that were exacerbated by COVID.
- 05/05/2021
|
Neurocrine Biosciences to Present at the Bank of America 2021 Healthcare Conference
- SAN DIEGO, May 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America 2021 Healthcare Conference at 11:00 a.m. Eastern Time on Tuesday May 11, 2021.
- 05/04/2021
|
Neurocrine Biosciences Supports Mental Health Month and Tardive Dyskinesia Awareness Week
- SAN DIEGO, May 3, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its support of Mental Health Month and commitment to raising awareness of and supporting people living with tardive dyskinesia (TD). Some people living with a mental health condition may also experience TD, an involuntary movement disorder that may develop after a few months of taking certain medications to treat bipolar disorder, depression and schizophrenia.1-3 The uncontrollable movements of TD, which can affect the face, torso and/or other body parts, may be disruptive to people's lives due to the symptoms and impact on their physical, emotional and social well-being.1,2,4 To help raise awareness of TD, the mental health advocacy community and states across the country are recognizing the first full week of May (2-8) as Tardive Dyskinesia Awareness Week for the fourth year in a row.
- 05/03/2021
|
Neurocrine Biosciences Announces Appointment of Johanna Mercier to Board of Directors
- SAN DIEGO, April 16, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Johanna Mercier to its Board of Directors. Ms. Mercier is the Chief Commercial Officer of Gilead Sciences, with responsibility for the global commercialization of Gilead's medicines.
- 04/16/2021
|
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2021 Financial Results
- SAN DIEGO, April 14, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report first quarter 2021 financial results after the Nasdaq market closes on Wednesday, May 5, 2021. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 p.m.
- 04/14/2021
|
Neurocrine Biosciences to Present Data from its Neurology Portfolio at the American Academy of Neurology's 73rd 2021 Virtual Meeting
- SAN DIEGO, April 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data from its movement disorders and epilepsy programs at the American Academy of Neurology's (AAN) 73rd Annual Meeting being held virtually from April 17–22, 2021. Key highlights include: Analysis from the KINECT 4 Phase III open-label study that demonstrated the effect of INGREZZA® (valbenazine) capsules on the overall severity of abnormal movements in adult patients living with tardive dyskinesia based on item 8 of the abnormal involuntary movement scale (AIMS) Phase III post-hoc sub-group data analysis that showed long-term use (one-year duration) of ONGENTYS® (opicapone) capsules in patients with Parkinson's disease with motor fluctuations reduced "on" time with troublesome dyskinesia and increased "on" time without troublesome dyskinesia New real-world data from EMPATHY, a retrospective medical chart review, highlight the need to simplify treatment regimens for patients with Parkinson's disease to manage motor fluctuations Results of an online caregiver survey include data on the relationship between genetic variants and disease characteristics in patients with SCN8A developmental epileptic encephalopathy (SCN8A-DEE) and SCN8A-related epilepsy Data from the Enroll-HD registry, a worldwide observational study, showed that the majority of patients with manifest Huntington disease have chorea, yet the majority of those with chorea were not prescribed medication to treat the condition.
- 04/08/2021
|
Strength Seen in Neurocrine (NBIX): Can Its 11.1% Jump Turn into More Strength?
- Neurocrine (NBIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 03/26/2021
|
Neurocrine Biosciences to Present at Stifel 3rd Annual CNS Day
- SAN DIEGO, March 25, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 3rd Annual CNS Day at 12:30 p.m. Eastern Time on Thursday Apr. 1, 2021.
- 03/25/2021
|
Why Neurocrine Biosciences Stock Jumped Today
- The stock is being added to a mid-cap index.
- 03/25/2021
|
NBIX Stock Price Increased Over 13% Intraday: Why It Happened
- The stock price of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has increased by over 13% during intraday trading. This is why it happened.
- 03/25/2021
|
Neurocrine Biosciences Set to Join S&P MidCap 400; O-I Glass to Join S&P SmallCap 600
- NEW YORK, March 24, 2021 /PRNewswire/ -- Neurocrine Biosciences Inc. (NASD:NBIX) will replace O-I Glass Inc. (NYSE:OI) in the S&P MidCap 400, and O-I Glass will replace HMS Holdings Corp (NASD:HMSY) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, March 30. Veritas Capital is acquiring HMS Holding in a deal expected to be completed soon pending final conditions.
- 03/24/2021
|
Neurocrine Biosciences to Present New Data Analyses for Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2021
- SAN DIEGO, March 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present additional positive data from its Phase II CAHlibrate study of crinecerfont, an investigational, oral, non-steroidal corticotropin-releasing factor type 1 (CRF1) receptor antagonist for the potential treatment of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD), at ENDO 2021, the Endocrine Society's annual meeting, on March 20–23, 2021. These new analyses, based on data from seven male subjects with classic CAH receiving crinecerfont, demonstrate dose-dependent decreases in androstenedione (A4), a key marker of CAH control and precursor to testosterone, with similar dose-dependent decreases in the A4 to testosterone ratio.
- 03/20/2021
|
5 Analyst Favorite Stocks to Buy for Q2 That Could Be Huge Winners
- Just like that, we are less than two weeks from the end of the first quarter. While it has been a very positive one for investors, the rise in interest rates has brought in much higher volatility and has really pressured technology stocks.
- 03/19/2021
|
The Sell-off In Neurocrine Stock Post Luvadaxistat Failure Is Unwarranted
- A few months back we discussed why Neurocrine Biosciences stock, a biotech company that develops treatments for neurological and endocrine-related diseases and disorders, looks oversold at $90 levels. Between mid-December 2020 to mid-February 2021, NBIX stock rallied over 30% from $90 to $120.
- 03/11/2021
|
Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference
- SAN DIEGO, March 9, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Oppenheimer 31st Annual Healthcare Conference at 4:30 p.m. Eastern Time on Tuesday Mar. 16, 2021.
- 03/09/2021
|
Sarepta, Vertex & Neurocrine: Out Of Favor Healthcare Stocks To Watch
- Our theme of Out Of Favor Health Care Stocks includes companies that have robust revenue growth and improving margins, and yet have not rallied much over the last year or so, due to Covid-19 related disruptions in the healthcare industry or due to some setbacks in their development pipelines.
- 02/24/2021
|
Neurocrine Biosciences Upping Marketing Spend To Support Its Platform
- Neurocrine Biosciences Upping Marketing Spend To Support Its Platform
- 02/09/2021
|
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q4 2020 Results - Earnings Call Transcript
- Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q4 2020 Results - Earnings Call Transcript
- 02/04/2021
|
Recap: Neurocrine Biosciences Q4 Earnings
- Shares of Neurocrine Biosciences (NASDAQ:NBIX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 13.33% year over year to $0.91, which beat the estimate of $0.54.
- 02/04/2021
|
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results
- SAN DIEGO, Feb. 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and full-year ended December 31, 2020 and provided full-year 2021 financial expense guidance. "In 2020, we served more patients with tardive...
- 02/04/2021
|
Neurocrine Sheds Its Parkinson's Gene Therapy Program, While The Street Waits For Ingrezza Reacceleration
- Neurocrine has chosen to terminate development of NBIb-1817, the gene therapy for Parkinson's it acquired through its partnership with Voyager.
- 02/03/2021
|
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
- Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/28/2021
|
Neurocrine, Ionis, Vertex: Underperforming Healthcare Stocks Poised To Recover
- Our theme of Out Of Favor Health Care Stocks includes health care stocks that have witnessed strong Revenue growth and improving fundamentals over the last few years but have underperformed in 2020, on account of clinical setbacks or due to Covid-19 related disruptions of the health care industry.
- 01/19/2021
|
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones
- SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update on its business performance, including preliminary net product and inventory adjusted sales results of INGREZZA® (valbenazine) for 2020, and key commercial and clinical development...
- 01/08/2021
|
5 Top Biotech Stocks to Buy for 2021 With Massive Upside Potential
- After an incredibly wild and wooly year for investors, many across Wall Street are cautiously optimistic for 2021.
- 12/21/2020
|
Neurocrine Stock Looks Attractive In the Wake Of A 30% Correction
- Neurocrine Biosciences stock, a biotech company that develops treatments for neurological and endocrine-related diseases and disorders, has more room for growth in the near term. NBIX stock is up just 14% off the recent bottom, significantly underperforming the S&P which moved 64% since its March.
- 12/16/2020
|
Neurocrine Biosciences Hit By Multiple Setbacks
- Neurocrine Biosciences reported disappointing sales of Ingrezza, as disruptions to clinical practice caused by COVID-19 have impacted new prescriptions, refills, and patient compliance. If COVID-19 is the true source of Ingrezza headwinds, quarterly sales growth could be under pressure through at least mid-2021.
- 11/17/2020
|
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2020 Results - Earnings Call Transcript
- Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2020 Results - Earnings Call Transcript
- 11/10/2020
|
Recap: Neurocrine Biosciences Q3 Earnings
- Shares of Neurocrine Biosciences (NASDAQ:NBIX) decreased 13.34% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 7.78% year over year to $0.97, which beat the estimate of ($0.06).
- 11/09/2020
|
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
- SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences: Kevin Gorman, Chief Executive Officer, and Kyle Gano, Chief Business Development and Strategy...
- 11/09/2020
|
Was The Smart Money Wrong About Neurocrine Biosciences, Inc. (NBIX)?
- Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren't timid and registered double digit market beating gains. Financials, energy and industrial stocks aren't doing great but many of the stocks that delivered strong returns since March are still going very strong and hedge funds actually increased their positions in these stocks. In this article we will find out how hedge fund sentiment to Neurocrine Biosciences, Inc. (NASDAQ:NBIX) changed recently.
- 11/04/2020
|
Vertex, Neurocrine: Are These Out Of Favor Healthcare Stocks A Buy As Vaccine Nears?
- Our indicative theme of Out Of Favor Healthcare Stocks Poised For Gains is down by about -13% year-to-date, compared to the S&P 500 which is up by about 2% over the same period. This theme includes healthcare and pharmaceutical companies that have shown robust historical revenue growth.
- 11/03/2020
|
Alexion Pharmaceuticals: More Potential Ahead Despite Upbeat Guidance (NASDAQ:ALXN)
- Alexion’s just-released revision to 2020 revenue guidance suggests continuing top line momentum. Given the strong performance through the pandemic, we believe there is even more room for growth as margins hold up.
- 10/07/2020
|
After
- Rip van Winkle supposedly slept for 20 years. That’s a lot longer than the bond market, which finally seems to be waking up from its summer snooze.
More on that below. The...
- 10/06/2020
|
Government considers fast-tracking National Broadband Plan
- Covid crisis has highlighted importance of good broadband, says minister
- 09/23/2020
|
AbbVie: I Don't Wanna Miss This Thing (NYSE:ABBV)
- 2020 is shaping up to be another record year for AbbVie. Six months into the pandemic, AbbVie has mastered the crisis better than expected and once again demonstrated the power of its strong and resilient portfolio.
- 09/22/2020
|
An Apple For Powell: Fed Meeting, Cupertino Event Could Dominate Today's Action
- How does the market follow up “Merger Monday?” Today the fun rolls on with a product presentation from Apple Inc. (NASDAQ: AAPL), the start of a Fed meeting...
- 09/15/2020
|
Hailiang Education Group Inc. : Celebrates 25th Anniversary and Announces Two Strategic Projects and Three Major Actions in the New Era | MarketScreener
|
New Data Support The Idea That Neurocrine Biosciences Is Building A Credible Parkinson's Portfolio
- A clinical update on VY-AADC showed sustained improvements in on/off time and motor function, but the data don't support the idea that this is a truly game-changing therapy for Parkinson's.
- 09/14/2020
|
Cramer's lightning round: 'I think you hold Boeing'
- "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
- 08/20/2020
|
National Bank of Canada : Investments Announces August 2020 Cash Distributions for certain NBI Exchange-Traded Funds | MarketScreener
|
National Broadband Plan customers to get download speed boost
- Company delivering €3bn plan triples minimum download speed to 500mbps
- 08/14/2020
|
Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $268,221.88 in Stock
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Eiry Roberts sold 2,257 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $118.84, for a total transaction of $268,221.88. Following the transaction, the insider now owns 11,446 shares in the company, valued at approximately $1,360,242.64. The transaction […]
- 08/11/2020
|
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Sells $403,104.90 in Stock
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kevin Charles Gorman sold 3,390 shares of the firm’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $118.91, for a total transaction of $403,104.90. Following the sale, the chief executive officer now owns 438,021 shares in the company, valued at approximately […]
- 08/11/2020
|
Voyager Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates | MarketScreener
|
Xenon Pharmaceuticals, Inc. (XENE) CEO Simon Pimstone on Q2 2020 Results - Earnings Call Transcript
- Xenon Pharmaceuticals, Inc. (NASDAQ:XENE) Q2 2020 Earnings Conference Call August 06, 2020, 17:30 ET Company Participants Jodi Regts - VP, Corporate Affairs & IR Simon Pimstone - CEO & Director Ian Mortimer - President, CFO & Company Secretary Conference Call Participants Alex Thompson - Stifel Andrew Tsai - Jefferies Laura Chico - Wedbush Securities Eddie Hickman - Guggenheim Securities Antonia Borovina - Bloom Burton & Co.
- 08/09/2020
|
Fibre broadband plan includes €100 standard connection charge
- Carrigaline townlands to be first connected to National Broadband Plan network
- 08/08/2020
|
Dupont Capital Management Corp Purchases New Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- Dupont Capital Management Corp purchased a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 2,881 shares of the company’s stock, valued at approximately $351,000. Other institutional investors also recently modified their holdings […]
- 08/05/2020
|
NASDAQ Rises for Fifth Straight Day and Logs Another New High
- Stocks Analysis by Zacks Investment Research covering: McDonald’s Corporation, Neurocrine Biosciences Inc, Diebold Nixdorf Inc, Treehouse Foods Inc. Read Zacks Investment Research's latest article on Investing.com
- 08/05/2020
|
Building An Investment Portfolio: July 2020 Update And 3 Buys
- Don't underestimate the power of compounding of the growth stocks. The future growth may not always be priced in and may compensate even if you end up paying more.
- 08/04/2020
|
Charting a solid August start: S&P 500, Nasdaq stage latest summer breakouts
- Technically speaking, the U.S. benchmarks’ bigger-picture backdrop remains bullish amid a solid August start, writes Michael Ashbaugh.
- 08/04/2020
|
Neurocrine Biosciences Inc (NBIX) Q2 2020 Earnings Call Transcript
- NBIX earnings call for the period ending June 30, 2020.
- 08/04/2020
|
Ingrezza Remains Surprisingly Strong For Neurocrine (NASDAQ:NBIX)
- Ingrezza sales, boosted by inventory-building, once again posted a double-digit beat to expectations, as sales grew 48% from the prior year.
- 08/04/2020
|
How Is Neurocrine Biosciences' (NASDAQ:NBIX) CEO Paid Relative To Peers?
- This article will reflect on the compensation paid to Kevin Gorman who has served as CEO of Neurocrine Biosciences...
- 08/04/2020
|
How Neurocrine Biosciences Crushed It in Q2
- Neurocrine Biosciences' (NASDAQ: NBIX) 30% plunge earlier this year during the coronavirus-fueled market meltdown is practically all but forgotten now. Here's what you need to know about Neurocrine's impressive Q2 update. Neurocrine reported revenue of $302.4 million in the second quarter, a 65% increase from the $183.5 million reported in the prior-year period.
- 08/04/2020
|
Number fever: The Pepsi contest that became a deadly fiasco
- DECADES ago, a marketing stunt promised Philippine soda drinkers a chance at a million pesos. But an error at a bottling plant led to 600,000 winners—and to lawsuits, rioting, and even deaths.
- 08/04/2020
|
Nisa Investment Advisors LLC Sells 14,860 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- Nisa Investment Advisors LLC decreased its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 65.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,836 shares of the company’s stock after selling 14,860 shares during the quarter. Nisa Investment Advisors LLC’s holdings in […]
- 08/04/2020
|
The Daily Biotech Pulse: Voyager, AbbVie End Collaboration, Thumbs Down For DBV's Peanut Allergy Patch, Tiziana Expedites COVID-19 Trial Plans
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
ABIOMED, Inc. (NASDAQ: ABMD)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Annexon Inc (NASDAQ: ANNX)
Atossa...
- 08/04/2020
|
Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates
- Neurocrine (NBIX) delivered earnings and revenue surprises of 24.62% and 18.28%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/03/2020
|
Neurocrine Biosciences Stock Pops After Earnings Double, Shatter Views
- Late Monday, Neurocrine Biosciences reported second-quarter earnings that doubled the year-earlier figure, shattering analyst expectations and sending shares of NBIX stock higher after hours.
- 08/03/2020
|
Neurocrine Biosciences Reports Second Quarter 2020 Financial Results
- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2020 and provided revised full-year 2020 financial expense guidance.
- 08/03/2020
|
Zurcher Kantonalbank Zurich Cantonalbank Has $2.71 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 17.1% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 22,207 shares of the company’s stock after purchasing an additional 3,238 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Neurocrine […]
- 08/03/2020
|
Winning the cold war with China will require a stronger military and a more inventive economy
- The United States must counter the rise of China with a stronger military and a renewal of the U.S. economy.
- 08/03/2020
|
Vident Investment Advisory LLC Increases Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- Vident Investment Advisory LLC grew its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 58.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,264 shares of the company’s stock after purchasing an additional 3,805 shares during the quarter. Vident […]
- 08/03/2020
|
Janney Montgomery Scott LLC Buys 172 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- Janney Montgomery Scott LLC increased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,888 shares of the company’s stock after purchasing an additional 172 shares during the period. Janney Montgomery Scott LLC’s holdings […]
- 08/03/2020
|
COVID-19 Impacts: Post-Traumatic Stress Disorder (PTSD) Therapeutics Market will Accelerate at a CAGR of Over 9% through 2020-2024 | Rising Prevalence of PTSD to Boost Growth | Technavio
- The Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market will grow by USD 909.86 mn during 2020-2024
- 08/03/2020
|
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
- Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
- 08/02/2020
|
Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference 2020
- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the William Blair Biotech Focus Conference 2020 at 12:00 p.m. ET on Thursday, August 6, 2020. Kyle Gano, Chief Business Development and Strategy Officer, will participate in a panel session titled "New Therapies Impacting the Epilepsy Treatment Landscape" at the conference.
- 07/30/2020
|
Charting a (bullish) holding pattern, S&P 500 digests break to 5-month highs
- The major U.S. benchmarks are acting well technically, though amid increasingly sideways late-July price action, writes Michael Ashbaugh.
- 07/28/2020
|
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
- Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/27/2020
|
Mizuho Boosts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $127.00
- Neurocrine Biosciences (NASDAQ:NBIX) had its price objective boosted by Mizuho from $105.00 to $127.00 in a report released on Thursday morning, The Fly reports. The brokerage currently has a neutral rating on the stock. NBIX has been the subject of a number of other research reports. Royal Bank of Canada increased their target price on […]
- 07/27/2020
|
Idorsia: A Unique Opportunity To Buy Discounted Shares
- A unique opportunity has developed for investors looking for a biotech to add to their portfolio. I will explain why the recent Cilag Holding decision has been misconstrued by some investors.
- 07/21/2020
|
Charting a bull-flag breakout, S&P 500 extends rally as volatility recedes
- Technically speaking, the U.S. benchmarks’ bigger-picture backdrop remains bullish, and continues to strengthen, amid recently receding volatility, writes...
- 07/21/2020
|
Three health-care stocks to watch as sector hits records
- Health-care stocks keep hitting highs. Mark Newton of Newton Advisors and Danielle Shay of Simpler Trading share their favorite names.
- 07/21/2020
|
Frontier Capital Management Co. LLC Makes New Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- Frontier Capital Management Co. LLC purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 40,362 shares of the company’s stock, valued at approximately $4,924,000. A number of other institutional investors have also bought […]
- 07/20/2020
|
Metrica Partners Sends Letter to Board of NBI Industrial Finance
|
Metrica Partners Sends Letter to Board of NBI Industrial Finance
- Metrica Partners Pte. Ltd. (“Metrica”) manages investment funds that are among the largest minority shareholders of NBI Industrial Finance Co. Ltd. (“
- 07/20/2020
|
Neurocrine Biosciences, Inc. to Post Q2 2020 Earnings of $0.39 Per Share, William Blair Forecasts (NASDAQ:NBIX)
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities research analysts at William Blair increased their Q2 2020 earnings estimates for Neurocrine Biosciences in a note issued to investors on Thursday, July 16th. William Blair analyst M. Minter now anticipates that the company will post earnings per share of $0.39 for the quarter, up from their previous forecast […]
- 07/18/2020
|
National Bank of Canada : Investments announces changes to portfolio managers | MarketScreener
|
National Bank of Canada : Investments Announces July 2020 Cash Distributions for certain NBI Exchange-Traded Funds | MarketScreener
|
Building A 'No-Brainer' Portfolio Today: 3 Fundamental Elements
- You don't need to lock yourself into a particular kind of investing style (e.g., dividend). No one can stop you from holding both AMZN and AT&T at the same time.
- 07/15/2020
|
'GILDing' the Lilly: COVID Progress in Spotlight Ahead of Health Sector Earnings
- Stocks Analysis by JJ Kinahan covering: S&P 500, Eli Lilly and Company, Gilead Sciences Inc, Medtronic PLC. Read JJ Kinahan's latest article on Investing.com
- 07/15/2020
|
Charting a bull-trend whipsaw, S&P 500 nails next resistance
- Technically speaking, the U.S. benchmarks have registered a mid-July market whipsaw, writes Michael Ashbaugh, pressured at least briefly amid the month’s...
- 07/14/2020
|
Did Hedge Funds Make The Right Call On Neurocrine Biosciences, Inc. (NBIX)?
- We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]
- 07/13/2020
|
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2020 Financial Results
- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter financial results after the Nasdaq market closes on Monday, August 3, 2020. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
- 07/13/2020
|
The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 9)
Affimed NV (NASDAQ: AFMD)...
- 07/10/2020
|
Axa Has $6.94 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- Axa boosted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 8.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 80,200 shares of the company’s stock after acquiring an additional 6,108 shares during the period. Axa owned 0.09% of Neurocrine Biosciences worth […]
- 07/06/2020
|
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Engineers Gate Manager LP
- Engineers Gate Manager LP cut its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 88.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,706 shares of the company’s stock after selling 21,399 shares during the period. Engineers Gate Manager LP’s […]
- 07/04/2020
|
Philippines probes deadly police shooting of soldiers
- MANILA (AFP): Philippine authorities are investigating the deaths of four soldiers shot by police in the country's restive south, with the defence minister vowing Thursday (July 2) to "get to the bottom" of the incident
- 07/02/2020
|
Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Pfizer (NYSE: PFE) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurocrine (NBIX
- 07/02/2020
|
Nasdaq's $1.2trn biotech index draws Europe's coronavirus vaccine hunters - LearnBonds.com
- Pharma Mar to become the latest company with US IPO interest as it prepares to join Nasdaq's $1.2 trillion biotech index on investor interest. Read more.
- 07/01/2020
|
From Parkinson's to peanut allergy, pandemic puts brakes on new drugs
- Treatments for peanut allergy and Parkinson's disease are among U.S. drug launches that have been postponed by the COVID-19 pandemic as drugmakers struggle with disruptions to business, a Reuters review of filings and interviews with executives show.
- 07/01/2020
|
FOCUS-From Parkinson's to peanut allergy, pandemic puts brakes on new drugs
- Treatments for peanut allergy and Parkinson's disease are among U.S. drug launches that have been postponed by the COVID-19 pandemic as drugmakers struggle with disruptions to business, a Reuters review of filings and interviews with executives show. The Food and Drug Administration (FDA) has approved more than 30 new medicines since January, but at least five drugmakers including Bristol Myers Squibb, Sanofi , Neurocrine Biosciences, Endo Pharmaceuticals and Aimmune have changed their launch plans.
- 07/01/2020
|
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Guggenheim Capital LLC
- Guggenheim Capital LLC lessened its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 18.0% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 40,337 shares of the company’s stock after selling 8,860 shares during the quarter. Guggenheim Capital LLC’s […]
- 07/01/2020
|
From Parkinson's to peanut allergy, pandemic puts brakes on new drugs
- From Parkinson's to peanut allergy, pandemic puts brakes on new drugs
- 07/01/2020
|
Crestchic’s load banks support fire prevention strategies and ageing energy infrastructure in the US - DirectorsTalk
- Due to ageing electrical distribution systems in the United States, sections of the power grids are being switched off for repairs to mitigate wildfire risks. With parts of the grid turned off, United Rentals turned to Crestchic USA to provide the rental company with six 3.3MVA 480V Resistive Reactive load bank containers, which are used ...
- 06/30/2020
|
Neurocrine Biosciences (NASDAQ:NBIX) Downgraded to Neutral at Goldman Sachs Group
- Goldman Sachs Group cut shares of Neurocrine Biosciences (NASDAQ:NBIX) from a buy rating to a neutral rating in a report published on Monday, BenzingaRatingsTable reports. They currently have $135.00 price objective on the stock. Several other equities analysts have also recently weighed in on the company. JPMorgan Chase & Co. lifted their price objective on […]
- 06/30/2020
|
Chevron secures deal with BHP - DirectorsTalk
- Chevron has secured a domestic gas sale agreement with BHP Nickel West for the delivery of natural gas from the Wheatstone domestic gas facility in Western Australia. Set to begin in July, Chevron will supply BHP Nickel West with a total of 22 petajoules (PJ) of domestic gas over 3.5 years. Managing director Al Williams ...
- 06/29/2020
|
Norman Broadbent Group returns to profit - DirectorsTalk
- Norman Broadbent plc (AIM: NBB), a leading London listed Professional Services firm offering a diversified portfolio of integrated Leadership Acquisition & Advisory Services (Board & Leadership Search, Senior Interim Management, Research & Insight, Leadership Consulting & Assessment, and executive level Talent Solutions) – has announced its final results and annual accounts for the year ended ...
- 06/29/2020
|
NB Global Corporate Income Trust (NBI) to Issue Final Dividend of $0.01 on July 9th
- NB Global Corporate Income Trust (ASX:NBI) announced a final dividend on Friday, June 26th, MarketIndexAU reports. Stockholders of record on Thursday, July 9th will be given a dividend of 0.009 per share on Thursday, July 9th. This represents a dividend yield of 0.56%. The ex-dividend date is Wednesday, July 1st. The stock has a fifty […]
- 06/28/2020
|
Shorts place record bets against TSX equities ETF (Plus, seven well-managed preferred share funds and why bulls smell danger)
- A roundup of investment ideas for active investors
- 06/26/2020
|
Halozyme Therapeutics, Inc. : The resistance should give in | MarketScreener
|
Halozyme Therapeutics, Inc. : La résistance devrait casser | Zone bourse
|
Crestchic Loadbanks expands rental business into Ireland - DirectorsTalk
- Crestchic Loadbanks is expanding its hire and rental business, bringing the latest load bank and power testing solutions to the Irish market. As one of the world’s leading specialist manufacturers of load banks, Crestchic has the experience and expertise to reliably test power supplies in a range of industries, from Data Centres and Healthcare, through ...
- 06/26/2020
|
The Zacks Analyst Blog Highlights: LLY, ABBV, NBIX and RDY
- The Zacks Analyst Blog Highlights: LLY, ABBV, NBIX and RDY
- 06/25/2020
|
ETFs for investors who have flamed out in trying to pick their own preferred shares
- Here are seven to consider
- 06/25/2020
|
Woodside moves ahead with plans for drilling and subsea installation off Australia - DirectorsTalk
- Australian energy giant Woodside has filed its environment plans for the Greater Western Flank 3 and Lambert Deep development drilling and subsea installation activities to the Australian offshore regulator. After the filing on 16 June, Woodside’s plan is now under assessment by NOPSEMA. The energy giant proposes to undertake the Greater Western Flank-3 (GWF-3) development ...
- 06/25/2020
|
Northbridge Industrial Services returns to an operating profit for the first time in 4 years - DirectorsTalk
- Northbridge Industrial Services Plc (LON:NBI), the industrial services and rental company, today issued the following trading update for the period 1 January 2020 to 31 May 2020, following its Annual General Meeting which was held yesterday evening at 5PM at the Group’s head office in Burton on Trent. As previously noted in the full year results ...
- 06/25/2020
|
Vertex Pharmaceuticals : The trend should continue | MarketScreener
|
Vertex Pharmaceuticals : La tendance devrait se poursuivre | Zone bourse
|
New Nokia CEO will join a month earlier as firm makes 5G tech gains
- Nokia makes progress on 5G radio kit and secures major contracts
- 06/24/2020
|
Santos gets NSW government nod for $3.6b CSG project - DirectorsTalk
- The Berejiklian government has given its support for the proposed $3.6 billion Santos coal seam gasfield in northern NSW, saying it was critical for energy security and that it had limited environmental impacts. In its assessment released on Friday, the Planning Department said its “comprehensive suite of strict conditions” would ensure the controversial project was “in ...
- 06/24/2020
|
The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 23)
ACADIA Pharmaceuticals Inc...
- 06/24/2020
|
Alpine Immune Sciences, Inc. : The underlying trend is to the upside | MarketScreener
|
Alpine Immune Sciences, Inc. : La tendance est haussière | Zone bourse
|
Nokia chosen as key fibre-network supplier for National Broadband Plan
- National Broadband Ireland has chosen Nokia to deploy its fibre network technology as part of the National Broadband Plan.
- 06/23/2020
|
Nokia : un contrat avec Toyota, un autre avec l'Irlande | Zone bourse
|
Nokia : un contrat avec Toyota, un autre avec l'Irlande
- (CercleFinance.com) - Nokia a annoncé mardi avoir été sélectionné par Toyota afin de déployer un réseau sans fil industriel au sein d'un centre de conception et de fabrication basé à Fukuoka (Japon)
- 06/23/2020
|
The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout
- The following is a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 22)
ADC Therapeutics SA (...
- 06/23/2020
|
Leigh Creek progresses with flagship project - DirectorsTalk
- Leigh Creek Energy (LCK) has completed 12 months of environmental monitoring at its flagship project in South Australia following the finalisation of its pre-commercial demonstration (PCD) operations. The company has submitted the results to the Department for Energy and Mining for its review. LCK announced last week that it had been granted approval by the ...
- 06/22/2020
|
Ascentage Pharma Group International : Nouveau potentiel au-dessus de la résistance | Zone bourse
|
Xconomy: Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More
- The biggest life sciences deal this week involves a company that doesn’t discover or develop drugs, or even sell them. Yet its mark is found on
- 06/19/2020
|
3 Ultra-High-Growth Biopharma Stocks to Grab Now | The Motley Fool
- Can the run for Sarepta Therapeutics, Viela Bio, and Aptose Biosciences continue?
- 06/19/2020
|
|
|
Neurocrine Further Expands Its Pipeline With An Early-Stage Deal
- Neurocrine and Takeda sign a partnership that brings potentially seven new drugs to Neurocrine for $120 million upfront. The lead drug, TAK-831, addresses the n
- 06/18/2020
|
Xconomy: Engrail Therapeutics Launches With $32M to Develop New Neuro Drugs
- Typically a new biotech assembles a group of investors that collectively puts in the money a fledgling company requires to develop or acquire potential
- 06/18/2020
|
Neurocrine Biosciences和武田宣布合作开发和商业化精神疾病潜在治疗药物
- (美国商业资讯)--Neurocrine Biosciences, Inc. (Nasdaq:NBIX)和武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)（“武田”）今天宣布一项旨在开发和商业化武田早期至中期精神
- 06/18/2020
|
Neurocrine Adds to Pipeline With $2 Billion Takeda Deal
- Biotech gets 7 drugs in partnership, 3 of which are in phase 2 testing Continue reading...
- 06/17/2020
|
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (NYSE: BHC), IDEAYA Biosciences (NASDAQ: IDYA) and Neurocrine (NASDAQ: NBIX) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bausch Health
- 06/17/2020
|
Viva plots natural gas imports to key Victorian city - DirectorsTalk
- Viva Energy believes Geelong in Victoria is well posited for the company to establish a liquefied natural gas (LNG) import, supply and storage facility. The company expects the project would bring natural gas from other parts of Australia and abroad to Victoria, with the virtual pipeline increasing diversity and competition of gas supply. Viva is ...
- 06/17/2020
|
Neurocrine Biosciences (NASDAQ:NBIX) Receives New Coverage from Analysts at Needham & Company LLC
- Needham & Company LLC initiated coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a report published on Tuesday, TipRanks reports. The brokerage issued a hold rating on the stock. Other analysts have also issued reports about the stock. Royal Bank of Canada reaffirmed a buy rating and set a $104.00 price objective on shares of […]
- 06/17/2020
|
Oppenheimer Assigns a Buy Rating on Neurocrine (NBIX) - Markets
- In a report released today, Jay Olson from Oppenheimer assigned a Buy rating to Neurocrine (NBIX – Research Report), with
- 06/16/2020
|
Takeda Pharmaceutical : Neurocrine Biosciences et Takeda annoncent une collaboration pour le développement et la mise sur le marché de thérapies potentielles contre les troubles psychiatriques | Zone bourse
|
Neurocrine (NBIX) Gets a Hold Rating from Needham - Markets
- Needham analyst Alan Carr assigned a Hold rating to Neurocrine (NBIX – Research Report) today. The company’s shares closed last
- 06/16/2020
|
Comunicado do Business Wire :Takeda Pharmaceutical Company Limited & Neurocrine Biosciences, Inc.
- A Neurocrine Biosciences, Inc
- 06/16/2020
|
Ultragenyx Pharmaceutical: Near-Term Catalysts Offer Best Of Both Worlds (NASDAQ:RARE)
- Ultragenyx is awaiting two new FDA approvals in the coming weeks. Two more candidates are undergoing mid-stage studies with data readouts expected before the ye
- 06/16/2020
|
Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders
- Strategic partnership agreement provides Neurocrine Biosciences exclusive worldwide rights to early-to-mid-stage psychiatry pipeline compounds within Takeda’s Neuroscience portfolio Collaboration i…
- 06/16/2020
|
Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders
- Neurocrine Biosciences and Takeda announced a strategic collaboration for compounds in Takeda’s early-to-mid-stage psychiatry pipeline.
- 06/16/2020
|
The Chief Research Officer of Neurocrine is Exercising Options - Markets
- Yesterday it was reported that the Chief Research Officer of Neurocrine (NBIX – Research Report), Dimitri Grigoriadis, exercised options to
- 06/16/2020
|
Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders
- Neurocrine Biosciences and Takeda announced a strategic collaboration for compounds in Takeda’s early-to-mid-stage psychiatry pipeline.
- 06/16/2020
|
Neurocrine Biosciences to Present at the Bank of America Securities 2020 Napa Biopharma Conference
- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2020 Napa Biopharma Conference at 2:00 p.m. PT (5:00 p.m. ET) on Monday, June 22, 2020. Kevin Gorman, Chief Executive Officer, will present at the conference.
- 06/15/2020
|
Genmab A/S : The underlying trend is to the upside | MarketScreener
|
Genmab A/S : La tendance est haussière | Zone bourse
|
Maria Ressa Verdict: Journalist Found Guilty Of 'Cyber Libel', Could Face 6 Years In Prison
- Maria Ressa, a former CNN bureau chief and a foe of Philippine strongman Rodrigo Duterte, is convicted of "cyber libel."
- 06/15/2020
|
3D Oil finalises Otway farmout with ConcoPhillips - DirectorsTalk
- 3D Oil has completed the farmout of T/49P in the Otway Basin to ConocoPhillips following approval from the National Offshore Petroleum Titles Authority (NOPTA). Under the terms of the joint operating agreement (JOA), ConocoPhillips will hold an 80 per cent interest in the permit and become operator. As a result, 3D Oil will receive a ...
- 06/15/2020
|
William Blair Reiterates Their Buy Rating on Neurocrine (NBIX) - Markets
- William Blair analyst Myles Minter reiterated a Buy rating on Neurocrine (NBIX – Research Report) on June 8. The company’s
- 06/12/2020
|
Queensland unlocks additions land for gas explorers - DirectorsTalk
- Gas explorers will have the chance to further develop Queensland gas country with the state government releasing 1500km2 of land in the state’s southwest. Queensland Mines Minister Anthony Lynham said five parcels were to be released for tender on June 18 around Moonie and Injune in the resource-rich Surat and Bowen Basins. This follows last month’s ...
- 06/12/2020
|
Feeling lonely? How to manage mental health challenges during social isolation
- (BPT) - This article was sponsored and developed by Neurocrine Biosciences Inc. As millions of people around the country practice social distancing and are staying at home for weeks on end, many people may find themselves feeling lonely and alone, maybe even anxious or uneasy, for the first time.
Others are all too familiar with the emotional impact of feeling alone and separated from friends and loved ones while also managing their emotional health. Among them are people who live with a mental illness such as depression, bipolar disorder and anxiety, who sometimes opt to social distance because being around other people makes them uncomfortable or self-conscious.
One in five adults live with some form of mental illness in the U.S., and many of them also deal with a relatively unknown involuntary movement disorder called tardive dyskinesia (TD). TD is associated with prolonged use of antipsychotics prescribed to treat mental illnesses such as depression, bipolar disorder, and schizophrenia. The physical symptoms of TD can impact one's emotional and social well-being, causing them to feel embarrassed or withdrawn from society. At least 500,000 people in the U.S. are living with TD.
Shelly, a married mother of one, was diagnosed with bipolar disorder and spent two years with her physician trying to find an antipsychotic medication that helped. After being prescribed a few different options, she finally found a treatment that worked for her. Just as things started to get better, however, she began noticing uncontrollable movements in her legs, mouth, and tongue.
After noticing these movements, her doctor advised that she might have TD. She learned that while the...
- 06/11/2020
|
EnergyQuest records east coast gas supply increase - DirectorsTalk
- East coast gas supply has increased marginally by 4 petajoules (PJ) from 458.2 PJ to 462.2 PJ in the first quarter of 2020, despite a decrease in conventional production by 9.7 PJ, the lowest since 1998. Outlined in EnergyQuest’s June report, east coast liquified natural gas (LNG) exports increased by 5.7 PJ to 310.7 PJ, ...
- 06/11/2020
|
Alexion Pharmaceuticals: Patent Resolution Is Too Little Too Late (NASDAQ:ALXN)
- The patent disputes over the leading drug forced Alexion to seek the revenue diversification. The recent acquisitions are unlikely to accelerate the current gro
- 06/10/2020
|
Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $134
|
Mahalo Gas Project Receives State Environmental Approval - DirectorsTalk
- Comet Ridge Limited (ASX:COI) is pleased to announce that the Mahalo Gas Project (MGP) has been granted Queensland State Government environmental approval for the gas development. This is the second of twoenvironmental stepsrequired for the project to move forward to production and follows the Commonwealth Government Environment Protection and Biodiversity Conservation Act (EPBC) approval in ...
- 06/10/2020
|
Neurocrine Biosciences (NASDAQ:NBIX) Now Covered by Wedbush
- Investment analysts at Wedbush began coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $147.00 price target on the stock. Wedbush’s price objective would indicate a potential upside of 23.72% from the stock’s current price. […]
- 06/10/2020
|
Full Phase II Data Reinforces Crinecerfont As A Serious Opportunity For Neurocrine Biosciences (NASDAQ:NBIX)
- Neurocrine's full Phase II data presentation on crinecerfont in adult patients with CAH didn't have many surprises, but the positive efficacy and safety data we
- 06/09/2020
|
Benzinga's Top Upgrades, Downgrades For June 9, 2020
|
Wedbush Initiates Coverage On Neurocrine Biosciences with Outperform Rating, Announces Price Target of $147
|
More gas exploration acreage made available in Queensland - DirectorsTalk
- The Queensland government will open a further 1 500 km2 of land in the south-west for gas exploration. Mines Minister Dr Anthony Lynham said five parcels were to be released for tender on June 18 around Moonie and Injune in the resource-rich Surat and Bowen basins. “It’s essential that we keep exploration underway to identify the resources projects ...
- 06/09/2020
|
Neurocrine Biosciences Reports Positive Phase II Data for Crinecerfont in Adults with Congenital Adrenal Hyperplasia at ENDO Online 2020
|
/C O R R E C T I O N -- Neurocrine Biosciences, Inc./
- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive data from its completed open-label, multiple-dose, dose-finding, Phase II clinical study of crinecerfont (NBI-74788), demonstrating meaningful reductions in all three key disease hormone markers in adult patients with classic congenital adrenal hyperplasia (CAH), a genetic disorder affecting the adrenal glands. Crinecerfont treatment produced meaningful reductions in elevated adrenocorticotropic hormone (ACTH) and 17-hydroxyprogesterone (17-OHP) levels (by 54% to 75%) at all doses studied, together with a dose-related decrease in androstenedione (A4) levels, ranging from 21% to 64% (Figure 1). At the highest dose of crinecerfont (100 mg twice daily), 75% of patients showed a response of at least 50% reduction from baseline for each of the three hormone markers at day 14 (Table 1). Treatment with crinecerfont was well tolerated with a favorable safety profile with no related serious adverse events reported. Adverse events reported in two or more participants included headache, upper respiratory tract infection, fatigue, contusion, insomnia and nausea. The full data set from the Phase II study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of crinecerfont, an investigational, oral, non-steroidal corticotropin-releasing factor type 1 (CRF1) receptor antagonist, is available as part of a recorded presentation at the Endocrine Society's ENDO Online 2020 meeting, can be accessed at this link, and on Neurocrine Biosciences' corporate website under Investors at www.neurocrine.com.
- 06/08/2020
|
Offshore regulator clears Santos’ plan for drilling location survey - DirectorsTalk
- National Offshore Petroleum Safety and Environmental Management Authority (NOPSEMA) has approved Santos’ plan for a geophysical survey in preparation for the proposed Yoorn-1 well drilling offshore Australia. NOPSEMA said that the environmental plan for the Yoorn-1 survey, located in permit area WA-499-P, was submitted in March 2020. According to the offshore regulator, the survey plan ...
- 06/08/2020
|
Wall Street Breakfast: The Week Ahead
- Welcome to Wall Street Brunch, our preview of stock market events for investors to watch during the upcoming week. You can also catch this article a day early b
- 06/07/2020
|
The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage
- The biotech space saw a flurry of activity last week, with coronavirus-related news, conference presentations and IPOs.
Negative clinical readouts led to some strong selling in...
- 06/07/2020
|
Stocks To Watch: Buzz On Vroom, Lululemon, GameStop And Sports Betting Plays
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 06/06/2020
|
Biotech Stock To Watch: Why This Leader Could Be Poised For Another Run
- Biotech company Neurocrine Biosciences is expected to deliver an update on a rare-disease program next week — offering a potential catalyst for NBIX stock, an analyst said Thursday.
- 06/05/2020
|
Biotech Stock To Watch: Why This Leader Could Be Poised For Another Run
- Biotech company Neurocrine Biosciences is expected to deliver an update on a rare-disease program next week — offering a potential catalyst for NBIX stock, an analyst said Thursday.
- 06/04/2020
|
Neurocrine Biosciences to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast at 9:40 a.m. ET on Thursday, June 11, 2020. Kevin Gorman, Chief Executive Officer, Eiry Roberts, Chief Medical Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will present at the conference.
- 06/04/2020
|
Santos awards KBR GLNG efficiency study contract - DirectorsTalk
- Santos has contracted KBR to undertake an energy efficiency opportunities study at its Gladstone liquified natural gas (GLNG) project in Queensland. The study will explore opportunities to improve the overall energy efficiency of the plant and reduce carbon dioxide (CO2) emissions associated with the GLNG liquefaction facility. KBR has reported that it will assist GLNG ...
- 06/04/2020
|
Investors will have to navigate these three post-pandemic market stages: Goldman Sachs
- Daily roundup of research and analysis from The Globe and Mail’s market strategist Scott Barlow
- 06/04/2020
|
Edited Transcript of NBIX earnings conference call or presentation 6-May-20 8:30pm GMT
- Q1 2020 Neurocrine Biosciences Inc Earnings Call
- 06/03/2020
|
APPEA emphasises industry role in Australian economy - DirectorsTalk
- Australian Petroleum Production and Exploration Association (APPEA) has highlighted the critical role oil and gas plays in providing energy to the Australian industry and households. The association’s key statistics 2020 publication has reaffirmed the importance of liquified natural gas (LNG) in supporting Australia’s economic resilience. Australia’s natural gas production (domestic use and LNG) increased by ...
- 06/02/2020
|
Beware Anchoring Bias: Top Stocks Now
- Focus more on businesses and less on anchoring to past prices. Uncertainty is increasing with the S&P 500 in no man's land. The best sectors across large cap, m
- 06/02/2020
|
AbbVie Gets FDA Nod for Oriahnn to Control Menstrual Bleeding
- The FDA approves AbbVie's (ABBV) Oriahnn oral capsule for checking heavy menstrual bleeding related to uterine fibroids in pre-menopausal women. It will be sold in US markets by June-end.
- 06/01/2020
|
May Market Wrap: Risks Remain But April's Rebound Continued Higher
- Stocks Analysis by Investing.com (Charley Blaine/Investing.com) covering: Nasdaq 100, S&P 500, Dow Jones Industrial Average, US SmallCap 2000. Read Investing.com (Charley Blaine/Investing.com)'s latest article on Investing.com
- 06/01/2020
|
The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight
- Biotech stocks could not sustain the uptrend in the holiday-shortened week, even as traders digested COVID-19-related news flow, clinical readouts, ASCO presentations and a few...
- 05/30/2020
|
Xconomy: AbbVie Wins First FDA Approval of Drug to Treat Uterine Fibroid Bleeds
- An AbbVie drug that treats pain in the uterus has notched an additional FDA approval for addressing heavy menstrual bleeding associated with uterine
- 05/29/2020
|
FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women
- AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (Nasdaq: NBIX), announced that the U.S. Food and Drug Administration (FDA) approved ORIAHNN™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules), with a treatment duration of up to 24 months.2 ORIAHNN is the first FDA-approved non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.2 ORIAHNN is expected to be available in the U.S. by the end of June 2020.
- 05/29/2020
|
Strike signs West Erregulla deal with AGIG - DirectorsTalk
- Strike Energy will partner with AGIG for the development of a 50 terajoules a day (TJ/day) plant for the processing of gas from the West Erregulla phase one development in Western Australia. As part of the long-term tolling arrangement, a gas facility will be constructed adjacent to the West Erregulla gas field in the Perth ...
- 05/29/2020
|
China Concerns Spark Late-Day Selloff
- Stocks Analysis by Zacks Investment Research covering: SPDR S&P 500, Adobe Systems Incorporated, Northern Trust Corporation, Akamai Technologies Inc. Read Zacks Investment Research's latest article on Investing.com
- 05/29/2020
|
Government wants to roll out National Broadband Plan in five years, not seven
- Minister Richard Bruton has tasked officials with seeing whether the €3bn National Broadband Plan could be rolled out faster than originally planned.
- 05/28/2020
|
The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas
|
Beach Energy preparing for drilling ops offshore New Zealand - DirectorsTalk
- Oil and gas company Beach Energy has applied for a consent to discharge trace amounts of harmful substances from the deck drains of a mobile offshore drilling unit (MODU) as it is preparing for exploration drilling in the Canterbury Basin off New Zealand, which could include up to 11 wells. The Environmental Protection Authority (EPA) ...
- 05/27/2020
|
IFG Advisory LLC Sells 2,278 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- IFG Advisory LLC trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 49.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,329 shares of the company’s stock after selling 2,278 shares during the period. IFG Advisory […]
- 05/27/2020
|
Neurocrine Biosciences to Present at the Jefferies Virtual Healthcare Conference
- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Jefferies Virtual Healthcare Conference at 11:00 a.m. ET on Tuesday, June 2, 2020. Kevin Gorman, Chief Executive Officer, will present at the conference.
- 05/26/2020
|
Stocks That Hit 52-Week Highs On Tuesday
|
Are Investors Undervaluing Neurocrine Biosciences, Inc. (NASDAQ:NBIX) By 33%?
- How far off is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) from its intrinsic value? Using the most recent financial...
- 05/26/2020
|
King Review offers Australia emission reduction opportunities - DirectorsTalk
- Santos expects that Australia is on a path to develop its carbon capture and storage (CCS) industry following the release of the King review and the federal government’s response. Kevin Gallagher, Santos managing director and chief executive officer, said the review made ‘sensible, job-creating’ recommendations that would cut through red and green tape to accelerate ...
- 05/26/2020
|
Research Report with COVID-19 Forecasts - Post-traumatic Stress Disorder Therapeutics Market 2020-2024 | Rising Prevalence of PTSD to Boost Growth | Technavio
- The post-traumatic stress disorder therapeutics market size will grow by USD 909.86 million during 2020-2024
- 05/25/2020
|
Teladoc, Neurocrine Bio Lead Five Healthy Stocks To Monitor Closely
- Several top health care stocks are in buy zones or setting up, including Teladoc and Neurocrine Biosciences. They are all worth adding to your watchlist.
- 05/23/2020
|
Xenon Pharmaceuticals Inc (NASDAQ: XENE) Q1 2020 Earnings Call Transcript | AlphaStreet
- Final earnings conference call transcript of Xenon Pharmaceuticals Inc. - XENE stock
- 05/22/2020
|
Strike Energy partners with AGIG in major gas processing infrastructure deal - DirectorsTalk
- Strike Energy has partnered with Australian gas infrastructure leader AGIG as the preferred proponent to design, build, own and operate a 50TJ/day gas plant for the processing of Strike’s gas from the proposed Phase 1 West Erregulla development under a long-term tolling arrangement. The gas facility will process raw gas to sales specification before delivering it into WA’s gas transmission ...
- 05/22/2020
|
|
|
